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Abstract 
Discovery of cancer drivers has traditionally focused on the identification of protein-
coding genes. Here we present a comprehensive analysis of putative cancer driver 
mutations in both protein-coding and non-coding genomic regions across >2,500 
whole cancer genomes from the Pan-Cancer Analysis of Whole Genomes (PCAWG) 
Consortium. We developed a statistically rigorous strategy for combining significance 
levels from multiple driver discovery methods and demonstrate that the integrated 
results overcome limitations of individual methods. We combined this strategy with 
careful filtering and applied it to protein-coding genes, promoters, untranslated 
regions (UTRs), distal enhancers and non-coding RNAs. These analyses redefine the 
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landscape of non-coding driver mutations in cancer genomes, confirming a few 
previously reported elements and raising doubts about others, while identifying novel 
candidate elements across 27 cancer types. Novel recurrent events were found in the 
promoters or 5’UTRs of TP53, RFTN1, RNF34, and MTG2, in the 3’UTRs of NFKBIZ and 
TOB1, and in the non-coding RNA RMRP. We provide evidence that the previously 
reported non-coding RNAs NEAT1 and MALAT1 may be subject to a localized 
mutational process. Perhaps the most striking finding is the relative paucity of point 
mutations driving cancer in non-coding genes and regulatory elements. Though we 
have limited power to discover infrequent non-coding drivers in individual cohorts, 
combined analysis of promoters of known cancer genes show little excess of 
mutations beyond TERT. 
 
 
Introduction 
Discovery of cancer drivers has traditionally focused on the identification of  
recurrently mutated protein-coding genes. Large-scale projects such as The Cancer 
Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) have 
profiled the genomes of a number of different cancer types to date, leading to the discovery 
of many putative cancer genes. Whole-genome sequencing (WGS) has made it possible to 
systematically survey non-coding regions for potential driver events. Recent studies of 
single-nucleotide variants (SNVs) and insertions/deletions (indels) detected from WGS data 
from smaller cohorts of patients have revealed putative candidates for regulatory driver 
events1–8. However, to date, only a few events have been functionally validated as regulatory 
drivers, affecting expression of one or more target genes by changing their regulation, RNA 
stability or disruption of normal genome topology6,9–12. Non-coding RNAs play diverse 
regulatory roles and are enzymatically involved in key steps of transcription and protein 
synthesis. Though functional evidence for non-coding RNAs in cancer is accumulating13,14, 
only few examples have been shown to be the target of recurrent mutation15,16. In contrast to 
protein-coding regions, the lower coverage and complexity of DNA sequence in these non-
coding regions pose additional challenges for high-quality mutation calling, mutation rate 
estimation and identification of driver events. Adequate statistical methods that address 
these issues are needed to identify non-coding drivers from these data. 
 
The ICGC and TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) effort, which has 
collected and systematically analyzed >2,700 cancer genome sequences from >2,500 
patients representing a variety of cancer types17, offers an unprecedented opportunity to 
perform a comprehensive analysis of putative coding and non-coding driver events. Here, 
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we describe results from multiple methods for detecting such drivers based on somatic 
SNVs and indels and a framework for integrating them. Using this approach, we identify 
significantly mutated genomic elements of various types in individual cancer types and 
across cancer types. We then use additional sources of information to remove from the initial 
list of significant elements those likely to result from mapping issues caused by repetitive 
regions or by inaccurate estimation of the local background mutation rate, and classify 
recurrently mutated elements as putative cancer-drivers or as likely false positives. Finally, 
we estimate our power to discover novel drivers in the PCAWG data set and evaluate the 
overall density of non-coding regulatory driver mutations around known cancer genes. 
 
Overview of recurrent mutations across cancer types 
Many protein-coding driver mutations and the two well-studied TERT promoter mutations 
occur in frequently mutated single base genomic “hotspots”. In order to obtain an initial view 
of these in the PCAWG data set, we generated a genome-wide list of highly mutated 
hotspots by ranking all sites in the genome based on the number of cancers that harbor 
somatic mutations in them. Only 12 genomic sites were recurrently somatically mutated in 
more than 1% (26) of cancers and 106 in more than 0.5%, while the vast majority (93.19%) 
of somatic mutations were private to a single patient’s cancer (Methods; Extended Data 
Fig. 1). Interestingly, although protein-coding regions span only ~1% of the genome, 15 
(30%) of the 50 most frequently mutated sites were known amino acid altering hotspots in 
known cancer genes (in KRAS, BRAF, PIK3CA, TP53, and IDH1) (Fig. 1a). Also among the 
top hits were the two TERT promoter hotspots. The top 50 list further contained a high 
proportion of mutations almost exclusively contributed by lymphoid malignancies (Lymph-
BNHL and Lymph-CLL) (18 hotspots) and melanomas (6). The melanoma-specific hotspots 
were located in regions occupied by transcription factors (5/6 in promoters), a phenomenon 
that has recently been attributed to reduced nucleotide excision repair (NER) of UV-induced 
DNA damage17–19. Indeed, signature analysis of the melanoma hotspot mutations attributed 
them to UV radiation (Fig. 1b). The hotspots in lymphoid malignancies reside in the IGH 
locus on chromosome 14, a known phenomenon in B-cell-derived cancers where IGH has 
undergone somatic hypermutation by the activation-induced cytosine deaminase (AID), an 
observation confirmed by mutational signature analysis (Fig. 1b). Hotspots in an intron of 
GPR126 and in the promoter of PLEKHS13,20 were located inside palindromic DNA that may 
fold into hairpin structures and expose single-stranded DNA loops to APOBEC enzymes3; 
accordingly, these mutations had high APOBEC signature probabilities. The six remaining 
non-coding hotspots could be attributed to a combination of mutational processes and 
presumed technical artifacts (Supplementary Note). In contrast to these non-coding and 
cancer-specific sites, mutations in protein-coding hotspots were attributed to the aging 
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signatures, or to a mixture of signatures. Our observation that, with the exception of the 
TERT promoter hotspots, all of the top non-coding hotspots are generated by highly 
localized, cancer-specific mutational processes suggests that these may be passengers.  
 
Next, we sought to systematically identify genomic elements that drive cancer by 
comprehensively analyzing SNVs and indels in transcribed and regulatory genomic 
elements, including protein-coding genes, promoters, 5’UTRs, 3’UTRs, splice sites, distal 
regulatory elements/enhancers, lncRNA genes, short ncRNAs, and miRNAs (in total ~4% of 
the genome) (Methods; Fig. 1c; Extended Data Fig. 2; Supplementary Table 1). Drivers 
can be common across many cancer types (such as TP53, PIK3CA, PTEN, and TERT 
promoter) or highly specific (e.g. CIC and FUBP1 in oligodendroglioma, BCR-ABL in chronic 
myelogenous leukemia, and FOXA1 in breast and prostate cancers). Analysis of large mixed 
tumor cohorts increases the power to discover common drivers but dilutes the signal from 
cancer-specific ones. In order to maximize our ability to detect common and cancer-specific 
drivers, we performed analyses of individual tumor types, tumors grouped by their tissue of 
origin or organ site (“meta-cohorts”), as well as a pan-cancer set (Fig. 1d; Methods). This 
aggregation of tumors by tissue or organ site further allowed us to take advantage of 
patients from cohorts too small to analyze individually (<20 patients). Overall, we analyzed 
2,583 unique patient samples in 27 individual tumor types and 15 meta-cohorts. 
 
Discovery of driver elements 
In order to identify bona fide drivers in each cohort, we collected and integrated results from 
multiple driver discovery methods. These methods identify statistically significant elements 
based on SNVs and indels and evidence from one or more of three criteria: (i) mutational 
burden, (ii) functional impact of mutation changes, and (iii) clustering of mutation sites in 
hotspots (Fig. 2a; Methods; Supplementary Table 2). Generally, mutational burden and 
clustering of events are independent of the type of genomic element that is tested for 
significance. The ability to use measures of functional impact, however, may vary greatly 
depending on the element type. In protein-coding genes, functional impact is assessed 
through the amino acid change introduced by a given mutation. For some non-coding 
elements, the impact of mutations on transcription factor binding sites, miRNA binding sites, 
or functional RNA structure may be predicted. However, in general, the exact consequences 
of somatic mutations are harder to assess in non-coding regions than in protein-coding 
regions, and may even vary substantially across cell types.  
 
Integration of results from multiple driver discovery methods 
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Most cancer genomic studies to date have employed a single method to identify putative 
cancer driver elements. This can introduce biases because the number and type of drivers 
detected by individual methods depends on their underlying assumptions and statistical 
model. To reach a comprehensive consensus list of candidate drivers, we collected the p-
values calculated by up to 16 driver discovery methods for each genomic element 
(Supplementary Table 2, 3) and derived a general strategy to integrate them (Fig. 2a). Our 
strategy accounts for the correlation of p-values among driver discovery methods that use 
similar approaches (burden, clustering, functional impact) when applied to the same data, 
while accumulating the independent evidence provided by different methods (Fig. 2b). To 
integrate potentially correlated statistical results, we used Brown’s method for combining p-
values21, an extension of the popular Fisher’s method22 (Fig. 2c). We first used simulated 
data sets that preserve local mutation rates and signatures but do not contain drivers, to 
assess the specificity of each method and the correlation structure among different methods 
when no genomic element is expected to have a significant excess or pattern of mutations 
(Methods; Extended Data Fig. 3). As anticipated, p-values were correlated among methods 
that share similar approaches. We then used the resulting correlation structure to integrate 
p-values from the observed (real) mutation data from different methods into a single p-value 
for each genomic element. Since simulated data sets are based on assumptions, we tested 
whether we can directly estimate the correlation structure from p-values calculated on the 
observed data. As this simpler approach yielded analogous results, it was used throughout 
this study (Methods, Extended Data Fig. 3). After additional filtering steps (see below), we 
conservatively controlled for multiple hypothesis testing using the Benjamini-Hochberg 
procedure (BH)23 across the 27 individual and 15 meta-cohorts, for each element type 
separately (Fig. 2e). Cohort-element combinations (hits) with q<0.1 (10% false discovery 
rate [FDR]) were considered significant. Overall, the union of all hits from the individual 
driver discovery methods contained 3,048 cohort-element pairs involving 1,694 unique 
elements, whereas the integrated results contained 1,406 significant hits with 635 unique 
elements (Supplementary Table 4, 5).  
 
Flagging and removal of potential false positive hits 
Even after careful variant calling, false positive identification of driver loci can arise from 
residual inaccuracies in background models, residual sequencing and mapping artifacts or 
from local increases in the burden of mutations generated by as-yet unmodeled mutational 
processes. To minimize technical issues, we carefully reviewed and filtered all candidate 
driver elements based on low-confidence mappability regions and site-specific noise in a 
panel of normal samples from PCAWG (Fig. 2d; Fig. 3a,b; Methods). For example, the 
lncRNA RN7SK is a small nuclear RNA with many homologous regions in the genome, 
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making it prone to read mapping errors (Fig. 3a), while a fraction of LEPROTL1 mutations 
fell in positions flagged by the site-specific noise filter (Fig. 3b).  
 
In addition, mutational processes not properly captured by current background models can 
cause local accumulation of mutations. As shown in the hotspot analysis above, events in 
the promoters of PIM1 and RPL13A are strongly associated with the AID and UV mutational 
processes, respectively, as previously noted18,19,24 (Fig. 3c). Moreover, DNA palindromes 
may form hairpin structures that expose loop bases to APOBEC enzymes, as has been 
proposed for PLEKHS1, GPR126, TBC1D12 and LEPROTL12,3 (Fig. 3d). Non-coding RNAs 
that form secondary structures often contain palindromic sequences, which could be 
preferential targets for APOBEC enzymes. However, only a small fraction of the mutations in 
structural RNAs appear to be APOBEC derived overall (4.8%) (Supplementary Note). In 
total, 569 out of 1,406 hits (element-cohort combinations with q<0.1) and 383 out of 635 
unique elements that were initially significant, were filtered out, resulting in 837 hits (Fig. 3e; 
Supplementary Tables 4, 5). Finally, multiple hypothesis correction was repeated after 
assigning a non-significant p-value (P = 1) to the filtered out hits, resulting in further removal 
of 91 candidate element-cohort combinations. 
 
Performance of the integration method 
To evaluate the sensitivity and validity of the integration approach, we compared the 
performance of individual methods and of the integration on protein-coding genes using, as 
a gold-standard, a list of 603 known recurrently-mutated cancer genes in the Cancer Gene 
Census25 (CGC v80). These analyses revealed that, typically, the integration of different 
methods outperformed individual methods, both in terms of sensitivity and specificity, 
yielding lists of significant genes that were longer and more enriched in high-confidence 
cancer genes (Extended Data Fig. 4). 
 
Discovery of recurrently mutated elements  
Our conservative integration and filtering strategy yielded 746 total hits, which include 646 
hits in 157 protein-coding genes, 30 hits in seven protein-coding promoters, 26 hits in eight 
long non-coding RNAs, 18 hits in six non-coding RNA promoters, ten hits in six 3’UTRs, six 
hits in four 5’UTRs, six hits in one enhancer, three hits in one microRNA and one hit in a 
small RNA candidate (Fig 4a; Supplementary Table 5). The number of significant elements 
varied from just one in clear-cell renal cancer to 78 in the Carcinoma meta-cohort (Fig. 4b) 
and depended strongly on cohort size (r = 0.84; P = 1.9x10-8; also see power analysis 
below), reflecting that the landscape of driver candidates, particularly in small tumor cohorts, 
is still incomplete. 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
7 
 
Comparison of the p-values obtained from individual tumor types and meta-cohorts revealed 
that although most candidate drivers gained significance in larger meta-cohorts, the tumor-
type specific genes DAXX (Panc-Endocrine), BRAF (Skin-Melanoma), NRAS (Skin-
Melanoma), SPOP (Prost-AdenoCa) and hsa-mir-142 (Lymph-BNHL) scored higher in their 
respective tumor types (Extended Data Fig. 5). These results emphasize the need for 
careful tradeoff between tumor-type specificity and cohort size when searching for drivers.  
 
Protein-coding mutations. The ability to discover known protein-coding cancer genes from 
WGS data provided the opportunity to evaluate our strategy and to put non-coding driver hits 
in context (Extended Data Fig. 6). Overall, candidate coding drivers were concordant with 
previous results: of the 157 genes significant in at least one patient cohort, 64% are listed in 
the CGC and 87% are in a more comprehensive list of cancer genes 
(https://doi.org/10.1101/190330). In contrast to prior studies based on large exome 
sequencing data sets, the moderate number of patients per cancer type in this data set 
provided sufficient power to detect only the genes with the strongest signal. Indeed, when 
we relaxed the significance threshold (q<0.25) to detect hits “near significance”, we found 93 
additional hits in 62 unique genes. Half (31) of these genes were already discovered as 
significant (q<0.1) in at least one cohort in this study, and now became significant in 
additional cohorts. Of the 31 genes not previously identified by our analyses, 19% were in 
the CGC and 32% in the more comprehensive list of drivers. These results confirm that 
many cancer genes were just beyond our significance threshold and would likely have been 
discovered with larger cohorts (Supplementary Table 4).  
 
Non-coding driver candidates 
In contrast to protein-coding elements, there was far less agreement among significance 
methods when analyzing non-coding elements, and most hits were strongly supported by 
only a few methods (Extended Data Fig. 7). The limited agreement between driver 
discovery methods in non-coding elements is likely due to a weaker signal of selection and 
different underlying assumptions that imperfectly model background mutation frequencies in 
non-coding regions. Thus, in order to nominate a significant element as a candidate driver, 
we carefully reviewed the supporting evidence from the genomic data and sought additional 
evidence from PCAWG (chromosomal breakpoints, copy-number, loss-of-heterozygosity and 
expression data), cancer gene databases and the literature (Supplementary Table 6).  
 
Promoters and 5’UTRs. Due to the overlap between the downstream regions of promoters 
and 5’UTRs, we reviewed the 11 significant elements from our promoter and 5’UTR 
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analyses together, yielding several interesting candidates. Our integrated results confirmed 
that the TERT promoter is the most significantly mutated promoter in cancer, being 
significant in 8 individual tumor types and 11 meta-cohorts (Fig. 4c; Supplementary Table 
5). As previously reported, we observed significantly higher TERT transcript expression 
levels in mutated compared to non-mutated cases (Extended Data Fig. 8).  
 
Among the remaining candidates, we found recurrent mutations in the promoters of PAX5 
and RFTN1 in lymphoma. PAX5 is a known off-target of AID hypermutation24 and, indeed, 
the percentage of its mutations attributable to AID activity (46%) was just below our filtering 
threshold. Consistently, mutations in its promoter were not associated with gene expression 
changes, suggesting that these mutations may be passengers (Extended Data Fig. 8). In 
contrast, mutations in the promoter of RFTN1 were weakly associated with an increase in 
RFTN1 expression levels (P = 0.03; mutant/wild type fold difference (FD) = 1.2; P = 0.02, 
after excluding 8/21 mutations attributed to the AID signature) (Fig. 5a). The protein 
encoded by RFTN1, Raftlin, associates with B-cell receptor complexes26 but its function in 
lymphoma is unclear. 
 
Mutations called in the 5’UTR of RNF34 in Liver-HCC overlap an intronic DNAse I 
hypersensitive region in multiple cell types27, suggesting that events may affect expression 
of RNF34 or a neighboring gene through an intragenic enhancer. Indeed, expression of the 
histone demethylase KDM2B located downstream of RNF34 shows weak correlation with 
these mutations (P = 0.03; FD = 1.3; Fig 5b) with no effect on RNF34 mRNA (P = 0.41). 
Mutations in the 5’ region of MTG2 were concentrated in a hotspot and showed marginally 
significant decreased expression in the Pan-cancer (P = 0.036; FD = 0.8) and Carcinoma (P 
= 0.029; FD = 0.8) meta-cohorts (Fig. 5c; Extended Data Fig. 8). MTG2 encodes a little-
studied GTPase that associates with the mitochondrial ribosome28. HES1 promoter 
mutations were significant in Carcinoma and Pan-cancer, but showed no association with 
gene expression (Extended Data Fig. 8). HES1 is a NOTCH signalling target29, and is 
focally amplified in gastric cancers (Extended Data Fig. 9).  
 
PTDSS1, DTL (and INTS7, which shares a bidirectional promoter), IFI44L and POLR3E 
showed trends towards increased or decreased expression in mutated tumors, although the 
small number of samples prevented us from drawing definitive conclusions (Extended Data 
Fig. 8). None of these genes were present in significantly amplified or deleted focal peaks 
(Methods). Validation of these hits with additional data in further studies will be needed to 
evaluate whether they are genuine drivers. 
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As previously reported in a number of studies1,3,7, we also found recurrent mutations in the 
promoter of WDR74, which was significant in multiple cohorts. The mutations concentrate in 
a small region overlapping an evolutionarily conserved spliceosomal U2 snRNA and 
therefore potentially affect splice patterns. However, no significant associations with either 
WDR74 or transcriptome-wide splicing were seen (Supplementary Note; Methods). We 
did, however, find that the repetitive U2 sequence was frequently affected by recurrent 
artifacts in SNP databases, raising concerns about potential mapping errors for this 
repetitive RNA type (Extended Data Fig. 10). 
 
Finally, restricted hypothesis testing of the promoters of CGC genes (n = 603) revealed 
significant recurrence of mutations in the promoter region of TP53 (11 patients in the pan-
cancer cohort; q = 0.044, NBR method). Most of these mutations were substitutions and 
deletions affecting either the TSS or the donor splice site of the first non-coding exon of 
TP53. For the 6 samples with expression data, these mutations were associated with a 
dramatic reduction of expression (Fig. 5d). In 8 of the 11 mutant cases, the mutation 
occurred in combination with copy-neutral loss of heterozygosity. This is the first report of a 
relatively infrequent, but impactful, form of TP53 inactivation by non-coding mutations. 
 
Enhancers. Two enhancer regions were found significant in our integration analysis; one at 
the IGH locus in Lymph-CLL and the other near TP53TG1 in multiple cohorts. However, 
many of the recurrent mutations in the enhancer overlapping the IGH locus are due to 
characteristic somatic hypermutation; 48% of mutations in this enhancer element matched 
the AID signature, which is just below our filtering threshold. Nine of 18 mutations in the 
enhancer near TP53TG1 were contributed by esophageal cancers. However, 89% of 
mutations in these esophageal tumors were attributed to a mutational signature common in 
this cancer type (mostly T>G substitutions in NTT context), raising the concern that these 
reflect a localized mutational process rather than a driver event30 (PCAWG7 publication). 
These mutations were concentrated around a conserved region (Fig. 5e) and overlapped 
sites bound by NFIC and ZBTB7 transcription factors in HepG2 cells27. TP53TG1 is a non-
coding RNA suggested as a tumor suppressor involved in p53 response to DNA damage 
and has been reported to be epigenetically silenced in cancer31. 
 
3’UTRs. Recurrent somatic events were identified in the 3’UTRs of six genes: FOXA1 in 
prostate cancer, ALB in liver cancer, SFTPB in lung adenocarcinoma, NFKBIZ and 
TMEM107 in lymphomas, and TOB1 in Carcinoma, most of which contained a large number 
of indels (Fig. 4c). High rates of indels in the 3’UTR of ALB in liver cancer and SFTPB in 
lung cancer have been recently reported8 but it is unclear whether they are cancer drivers or 
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the result of a poorly-understood mechanism of localized indel hypermutation. To determine 
whether indels affect function and accumulate specifically in the 3’UTRs, we compared indel 
rates in 3’UTRs with other regions around these genes. Consistent with local hypermutation, 
rather than selection, we observed similar indel rates in 3’UTR and 1 kb downstream of the 
polyadenylation site in ALB, SFTPB and FOXA1 (Fig. 6a). This, together with additional 
observations presented below, strongly suggest that indel recurrence at these loci is caused 
by a novel localized hypermutation process. 
 
On the other hand, although ALB is subject to localized hypermutation, protein-coding SNVs 
in ALB are enriched in missense and truncating events relative to synonymous mutations in 
liver cancer (P = 1.5x10-7; Fig. 6b). Furthermore, the ALB locus is lost in a fraction of liver 
cases (Fig. 6b), with copy losses having a tendency to occur in samples without somatic 
mutations (Fisher’s exact test, P = 0.0099). These findings, suggest that loss of ALB may be 
a genuine driver event in liver cancer. Similarly, the well-known driver role of FOXA1 in 
prostate tumors is supported by the functional impact of coding mutations (P = 4.4x10-7) and 
focal amplifications, raising the possibility that the mutation enrichment observed in the 
3'UTR might also be functional. 
 
In contrast to the genes discussed above, the number of indels in the 3’UTRs of NFKBIZ and 
TOB1 was significantly higher than in other parts of these genes, suggesting that indels in 
the 3’UTRs could be under functional selection (Fig. 6a). TOB1 encodes an anti-proliferation 
regulator that associates with ERBB2, and also affects migration and invasion in gastric 
cancer32. As part of the CCR4-NOT complex, TOB1 regulates other mRNAs through binding 
to their 3’UTR and promoting deadenylation33. Tumors with 3’UTR mutations in TOB1 
showed a trend towards decreased expression (P = 0.053; FD = 0.7). Mutations did not 
concentrate in known miRNA binding sites, possibly due to incomplete annotation (Fig. 6c). 
However, the extreme conservation of this region (5th most conserved among all tested 
3’UTRs with an average PhyloP score of 5.6) indicates that these events likely disrupt 
functionally important sites (Fig. 6c). Interestingly, TOB1 and its neighboring gene WFIKKN2 
are focally amplified in breast cancer and pan-cancer, suggesting a complex role in cancer 
(Extended Data Fig. 9). NFKBIZ is a transcription factor that is mutated in 
recurrent/relapsed DLBCL34 and amplified in primary lymphomas34,35. 3’UTR mutations 
accumulated in a hotspot proximal to the stop codon and upstream of conserved miRNA 
binding sites which might be affected by these mutations (Fig. 6d). Only two events in these 
regions are SNVs, suggesting that mutations in the NFKBIZ 3’UTR are not the consequence 
of AID off-target activity. Lymphomas with 3’UTR mutations showed a trend towards 
increased mRNA levels of NFKBIZ (P = 0.035; FD = 3.2; the trend remains after correction 
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for copy number, P = 0.03; Fig. 6d). Functional studies will be required to understand the 
exact function of 3’UTR mutations on transcript regulation of TOB1 and NFKBIZ. 
 
Mutations in the significant 3’UTR of TMEM107 in lymphoma overlap the U8 small RNA 
SNORD118 (Extended Data Fig. 10). Similar to WDR74, overlap with a repetitive RNA 
element suggests that these mutations might be caused by mapping artifacts. 
 
Non-coding RNAs. ncRNAs are often part of large gene families with multiple copies in the 
genome. Sequence similarity with other genomic regions may therefore complicate their 
analysis. Similarly to the U2 RNA upstream of WDR74, we observed high levels of germline 
polymorphisms in normal samples in some of the significant ncRNAs and their promoters 
(Extended Data Fig. 10). Though interesting candidates, caution should thus be exercised 
in interpreting these hits. 
 
The non-coding RNA RMRP is significantly mutated in multiple cancer types, in both its gene 
body and promoter (Fig 4c; Fig 6e; Supplementary Table 5). RMRP is the RNA 
component of the endoribonuclease RNase MRP, an enzymatically active 
ribonucleoprotein36,37,38. Its catalytic function depends on the RNA secondary and tertiary 
structure and its interactions with proteins39. Germline mutations in RMRP cause cartilage-
hair hypoplasia, and somatic promoter mutations have been reported to be functional9. In 
addition, the RMRP locus is focally amplified in several tumor types, including epithelial 
cancer (Extended Data Fig. 9c). SNVs in the gene body (7 in pan-cancer) are significantly 
biased towards secondary structure impact (P = 0.011, permutation test)40,41. Three of these 
are individually significant (each with P < 0.1, sample level permutation tests), with two 
affecting the same position and one located in a tertiary interaction site (Fig. 6e). Of the four 
gene-body indels, three are located in or near protein-binding sites (P = 0.08), including a 
deletion that is predicted to affect the secondary structure (Extended Data Fig. 9d). Given 
RMRP's role in replication of the mitochodrial genome36, we tested whether mutations in this 
locus were associated with altered mitochondrial genome copy number. Indeed, mutated 
samples showed a trend towards higher mitochondrial copy number (two-sided rank-sum 
test, P = 0.1). However, RMRP also appears to be a target of potential artifacts (Extended 
Data Fig. 10) and so its relevance to cancer requires further scrutiny. 
 
The microRNA precursor (pre-miRNA) for miR-142 was found significant in Lymph-BNHL, 
Lymphatic system and Hematopoietic system (Fig. 4c; Supplementary Table 5). The locus 
is a known AID off-target in lymphoma5,42(Extended Data Fig. 10). However, five of seven 
mutations (71%) in the dominantly expressed mature miRNA mir-142-p3, where the largest 
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functional impact is expected, were not assigned to AID, raising the possibility that they may 
be under selection5. 
 
Eleven additional ncRNA-related elements (RNU6-573P, RPPH1, RNU12, TRAM2-AS1, 
G025135, G029190,RP11-92C4.6 and promoters of RNU12, MIR663A, RP11-440L14.1, 
and LINC00963) passed our stringent post-filtering, but had limited supporting evidence after 
manual inspection. These are discussed in a Supplementary Note. We further checked 
whether any of our non-coding candidates were associated with known germline cancer risk 
variants, and found no significant associations, with the exception of TERT (Methods). 
 
NEAT1 and MALAT1, two neighboring lncRNAs previously reported as recurrently mutated 
in liver43 and breast cancer3, were found significant in multiple cohorts (Fig. 4c), mutated in a 
large number of patients (369 for NEAT1 and 158 for MALAT1; Fig 7a). In addition, these 
genes are significantly associated with nearby chromosomal breakpoints (NEAT1: P = 
5.3x10-9; MALAT1: P = 0.0012; Methods; Extended Data Fig. 11). The pattern of 
breakpoints, indels and SNVs scattered throughout their sequence would suggest a possible 
tumor suppressor role. To evaluate this hypothesis, we tested whether MALAT1 and NEAT1 
mutations are associated to loss of heterozygosity (LOH). Neither gene showed biallelic loss, 
in contrast to many known canonical tumor suppressors (Fig. 7b; Extended Data Fig. 11). 
Mutations in MALAT1 and NEAT1 also do not exhibit higher cancer allele fractions 
compared to mutations in flanking regions, a feature of early driver mutations (Fig 7c; 
Extended Data Fig. 11). Furthermore, NEAT1 and MALAT1 mutations are not associated 
with altered expression levels, suggesting that they do not affect post-transcriptional stability 
nor show increased expression like many mutated oncogenes (Fig 7d; Extended Data Fig. 
11). 
 
The high enrichment of indels throughout the gene body of NEAT1 and MALAT1, which 
have very high expression levels across many cancer types, resembles the phenomenon 
described above for ALB and SFTPB. If these indels are generated by a specific mutational 
process, we might expect distinct features from indels found elsewhere in the genome. 
Indeed, we find that indels in NEAT1, MALAT1, ALB and SFTPB are strongly enriched in 
events longer than 1 bp and particularly in indels of length 2-5 bp, compared to the genomic 
background (least significant Fisher’s P = 6.8x10-5, for MALAT1; Fig. 7e). The association of 
these indels with highly expressed genes suggests a transcription-coupled mutagenic 
mechanism, possibly transcription-replication collisions44–46. A systematic search of genes 
with increased rates of 2-5 bp indels reveals that this yet-unknown mutational process 
affects other highly expressed genes (Extended Data Fig. 11), some of which were reported 
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in a recent study8, indicating that these indel sizes are a feature of the reported mutational 
process. Interestingly, SNVs also occur at higher frequencies in these genes, suggesting 
that they may be generated by the same mechanism, although less frequently (Fig. 7f). 
 
Overall, the discovery of a localized mutational signature and the lack of association of the 
mutations in MALAT1 and NEAT1 with loss of heterozygosity or higher allele frequencies 
suggests that indels in these genes are most likely passenger events. The previously 
reported oncogenic phenotypes associated with both ncRNAs43,47,48 may thus be related to 
other types of alterations.  
 
Localized lack of power to call mutations 
Certain genomic regions, especially those with high GC content, are subject to systematic 
low coverage in next-generation sequencing49. We used power analysis to quantify the 
number of possibly missed mutations, especially in non-coding regions. These calculations 
attempt to account for variations in local sequencing depth, purity and overall ploidy of 
individual tumor samples, background mutation rates across cohorts and elements, and the 
size of patient cohorts9,50–52. We found that mutation detection sensitivity was high across the 
element types, (median d.s. = 0.98) but slightly lower for the typically GC-rich promoters 
(median d.s. = 0.96) and 5’UTR elements (0.96; Fig. 8a; Supplementary Table 4,5). 
However, for some individual genomic regions the detection sensitivity is dramatically 
reduced and it is therefore important to evaluate it for elements of interest. For example, only 
43% of tested cases have at least 50% average detection sensitivity across the third exon of 
TCF7L2 and 20% in the 5’UTR of AKT1 (Extended Data Fig. 12a). Positional detection 
sensitivities for the two canonical TERT promoter hotspot sites were highly variable among 
patients and cohorts, ranging from 4% of sufficiently powered (≥90%) patients in CNS-
PiloAstro to 100% of patients in Thy-AdenoCa (Fig. 8b; Extended Data Fig. 12b). This 
means that we have nearly no information about possible TERT promoter mutations in CNS-
PiloAstro and incomplete information in other cohorts. Using the detection sensitivity and 
observed mutation count at the TERT hotspot sites, we inferred the expected total number of 
events in each tumor type (Fig 8c). This analysis revealed that ~216 (CI95 = [188,245]) 
TERT hotspot mutations were likely missed in this study due to lack of power. Likewise, 
about four additional mutations would be expected at the recurrent FOXA1 promoter hotspot 
shown to be mutated in hormone-receptor positive breast cancers (Extended Data Fig. 
12)9. 
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These calculations suggest that a considerable number of potentially impactful somatic 
mutations were not detected due to systematic low sequencing coverage, and that specific 
positions can be unpowered in elements with overall sufficient coverage. 
 
We further evaluated the discovery power for recurrent events identified in mutational burden 
tests in the tumor cohorts analyzed in this study9,50. As expected, discovery power was 
highest in cohorts with many patients and low background mutation densities allowing 
discovery of typical-sized driver elements mutated in fewer than 1% of patients in the 
Carcinoma, Adenocarcinoma and pan-cancer meta-cohorts with 90% power (Fig. 8d). In 
contrast, the small Bladder-TCC cohort (n=23) with relatively high background mutation 
density (~2.7 mutations/Mb) is only powered to discover drivers that occur in at least 25% of 
patients (Fig. 8d). Overall, power differences between element types for individual tumor 
cohorts were small, suggesting that lack of power alone cannot explain the observed paucity 
of regulatory driver elements.  
 
Relative paucity of non-coding driver point mutations 
To further analyze the relative paucity of driver mutations in non-coding elements, we sought 
to estimate the overall number of driver mutations, in coding and non-coding regions of 
known cancer genes. Given the limited statistical power to detect individually significant 
elements, we combined the signal from multiple elements, as recently described53. The 
difference between the total number of mutations observed across a combined set of 
elements and the number of passenger mutations that is expected by chance, i.e. the 
excess of mutations, approximates the total number of driver mutations in the set of 
elements. To estimate the expected number of background mutations, we fit the NBR model 
to presumed passenger genes, controlling for sequence composition, element size and 
regional mutation densities (Methods; Supplementary Table 7; Supplementary Note)53. 
We focused on 142 known cancer genes that include the significantly mutated cancer genes 
in this study and frequently amplified or deleted cancer genes (Methods). We specifically 
excluded TERT from this analysis because of its high frequency of promoter driver mutations 
and the incomplete detection sensitivity reported above. 
  
Overall, this approach predicted an excess of 3,133 driver mutations (CI95% [2,987-3,273]; 
2,258 SNVs and 875 indels) in the protein-coding sequences of these genes across the pan-
cancer meta-cohort (Fig. 8e). In contrast to coding regions, the observed number of 
mutations across the combined set of non-coding elements associated with these genes is 
very close to the expected number of passenger mutations, , with an excess of 71 (CI95%:22-
133) mutations in promoters, 32 (0-79) in 5’UTRs, and 103 (25-184) in 3’UTRs. These 
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results indicate that coding genes contribute the vast majority (>90%) of driver point 
mutations in these 142 cancer genes. Importantly, these estimates are conservative, since 
the estimation of the background number of mutations from putative passenger genes may 
include yet undetected driver mutations. In addition, non-coding mutations in promoters of 
cancer genes were also not generally associated with LOH nor with altered expression, as 
one would expect if they were enriched with driver mutations (Supplementary Note). 
Altogether, our results suggest that mutations in protein-coding regions dominate the 
landscape of driver point mutations in known cancer genes. 
 
Discussion 
If we are to fulfill the ambitions of precision medicine, we need a detailed understanding of 
the genetic changes that drive each person’s cancer, including those in non-coding regions 
(https://doi.org/10.1101/190330). Most cancer genomic studies have focused on protein-
coding genes, leaving non-coding regulatory regions and non-coding RNA genes largely 
unexplored. The unprecedented availability of high-quality mutation calls from whole-
genomes of >2,500 patients across 27 cancer types has enabled us to comprehensively 
search for functional elements with cancer-driver mutations across the genome. To obtain 
reliable results and avoid common pitfalls in detecting drivers54, we have benchmarked a 
large number of methods and developed a novel and rigorous statistical strategy for 
integrating their results. 
 
Among the most interesting candidate non-coding driver elements identified in this analysis, 
we have uncovered promoter or 5’UTR mutations in TP53, RFTN1 and MTG2, a putative 
intragenic regulatory element in RNF34 that possibly regulates KDM2B; 3’UTR mutations in 
NFKBIZ and TOB1; and recurrent mutations in the non-coding RNA RMRP. We have also 
found evidence suggesting that a number of previously reported and frequently mutated 
non-coding elements may not be genuine cancer drivers. Particularly, the non-coding RNAs 
NEAT1 and MALAT1 are subject to a high density of passenger indels, seemingly due to a 
transcription-associated mutational process that targets some of the most highly expressed 
genes. 
 
Our study has yielded an unexpectedly low number of non-coding driver candidates. The 
results from four analyses - genomic hotspot recurrence, driver element discovery, discovery 
power and mutational excess - suggest that the regulatory elements studied here contribute 
a much smaller number of recurrent cancer-driving mutations than protein-coding genes. 
This contrasts the distribution of germline polymorphisms associated with heritability of 
complex traits, which are most frequently located outside of protein-coding genes 55. 
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Technical shortcomings, such as severe localized lack of sequence coverage in GC-rich 
promoters (as in the case of the TERT promoter), may lead to considerable underestimation 
of true drivers in certain regions. The yield of driver events will thus benefit from technical 
improvements, including less variable sequence coverage (e.g. PCR-free library 
preparation), longer sequencing reads and advanced methods for read mapping and variant 
calling that can overcome common artifacts. Moreover, studying larger tumor cohorts will 
provide increased power to discover infrequently mutated driver elements. 
 
Our analyses have focused on currently-annotated non-coding regulatory elements and non-
coding genes, comprising 4% of the genome, and exclusively on SNVs and indels. Although 
our genome-wide hotspot analysis did not detect novel highly recurrent non-coding mutation 
sites, it is possible that additional non-coding drivers reside outside of the regions tested 
here. Improvements in the functional annotation of non-coding elements, our understanding 
of their tissue-specificity, and the impact of mutations in them, will refine current driver 
discovery models and enable more comprehensive screens. 
 
A challenge in the identification of non-coding drivers is distinguishing real novel driver 
events from yet-unidentified mutational mechanisms targeting certain genomic regions, such 
as the recently described hypermutation of transcription factor binding sites in 
melanoma56,57. Better understanding of mutational processes and their activity along the 
genome will be critical to improve the sensitivity and specificity of statistical methods for 
driver discovery.  
 
One potential explanation for the relative paucity of non-coding drivers is the smaller 
functional territory size of many regulatory elements, and hence smaller chance of being 
mutated, compared to protein-coding genes (Extended Data Fig.1; Fig. 8d). The presence 
of TERT promoter mutations at just two sites suggests that non-coding driver mutations may 
be confined to specific positions, similar to the small number of impactful sites in the 
oncogenes BRAF, KRAS and IDH1.  
 
SNVs and small indels may not easily alter the function of non-coding regulatory elements. 
Directly mutating protein-coding sequences or altering expression levels by copy number 
changes, epigenetic changes or repurposing of distal enhancers through genomic 
rearrangements58,59 may be more likely to provide large phenotypic effects. While protein-
truncating or frameshift mutations can be created by a single nucleotide change, silencing 
regulatory regions of tumor suppressors may depend on large deletions to achieve a similar 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
17 
effect. Although the very high frequency of TERT promoter mutations in cancer 
demonstrates that some promoter point mutations can be potent driver events, our analyses 
suggest that the number of regulatory sites where a point mutation can lead to major 
phenotypic effects may be smaller than anticipated across the genome. This highlights 
TERT as an unusual example, perhaps because even a modest increase in the expression 
level of TERT may be sufficient for circumventing normal telomere shortening in cancer 
cells. 
 
Comprehensive and reliable discovery of non-coding driver mutations in cancer genomes 
will be an integral part of cancer research and precision medicine in the coming years. We 
anticipate that the approaches developed here will provide a solid foundation for the incipient 
era of driver discovery from ever-larger numbers of cancer whole-genome sequences. 
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Figure legends 
Figure 1: Mutational hotspots and overview of functional elements and meta-cohorts. 
a, Characteristics of top 50 single-site hotspots in PCAWG SNV data. The stacked bar chart 
(left) shows the total number of patients mutated across the PCAWG cohorts colored by 
mutation type. Gene names are given when hotspots overlap functional elements (colour-
coded). Known somatic driver sites are marked with a hashtag. Amino acid change is 
indicated for protein-coding genes. The genomic location (chr:position) is colored by overlap 
with center of palindromes (orange) or immunoglobulin loci (brown). The table (right) shows 
the distribution of hotspot SNVs in the PCAWG cohorts sorted by number of hotspots. 
Tumor-type specific hotspots are indicated with a box. This only includes cohorts with at 
least 20 patients, and at least 10 patients or 10% of patients with a SNV. The Lymph-BNHL 
and Lymph-CLL cohorts are shown together as Lymphoid malignancies. See Extended 
Data Fig. 1 for a complete set of individual and meta cohorts. b, Mutational signature 
attributions for mutations in each hotspot site. c, Schematic describing definition of functional 
element types from GENCODE and ENCODE annotation resources. Functional elements 
(black) are defined based on transcript annotations from various databases. Elements 
arising from multiple transcripts with the same gene ID are collapsed, as seen here for the 
protein-coding isoforms. Promoter elements are defined as 200 bases upstream and 
downstream of the transcription start sites of a gene's transcripts (marked with red). Splice 
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site elements extend 6 and 20 bases from 3' and 5' exonic ends into intronic regions 
respectively, as indicated. Regions overlapping protein-coding bases and protein-coding 
splice sites are subtracted from other regions, as indicated for the lncRNA promoter element 
in gray. d, Organization of meta-cohorts defined by tissue of origin and organ system 
(Methods). Pan-cancer contains all cancers excluding Skin-Melanoma and lymphoid 
malignancies. 
 
Figure 2: Filtering and integration process for nomination of driver candidates. a, 
Overview of driver discovery method and their lines of evidence to evaluate candidate gene 
drivers. Methods employing each feature are marked with blue boxes next to the appropriate 
track. b, Spearman’s correlation of p-values across the different driver discovery algorithms 
based on simulated (null model) mutational data. Dendrogram illustrates relatedness of 
method p-values and algorithm approaches marked by colored boxes on dendrogram 
leaves. c, P-values are combined with Brown’s method based on the correlation structure 
calculated in (b). Individual method (left) and integrated (right) log-transformed p-values are 
shown in a heatmap (grey: missing data). d, Post-filtering used several criteria to identify 
likely suspicious candidates (shaded grey rectangle). e, Significant driver candidates were 
identified after controlling for multiple hypothesis testing based on an FDR q-value threshold 
of 0.1 (blue asterisk). Candidates with q-values below 0.25 (blue dash) were also considered 
of interest. 
  
Figure 3: Technical and biological confounders used in candidate filtering. a, Read 
mappability based on alignability, uniqueness and blacklisted regions. Example shown for 
RN7SK, which was removed due to low alignability. b, Site-specific noise evaluated in 
normal samples from PCAWG. c, Increased local mutation density caused by AID and UV 
mutational processes in lymphoma and melanoma, respectively. d, Palindromic DNA can 
expose bases to APOBEC enzymes. f, Number of significant unique hits (left) and unique 
elements (right) removed by each filter. 
 
Figure 4: Protein-coding and non-coding driver elements identified in PCAWG 
cohorts. a, Number of total hits (elements significant in a certain patient cohort; left) and 
number of unique significant elements (right). b, Number of significant elements by type and 
by cohort. c, Significant non-coding elements identified in this study. Element types are 
indicated with colors as in Fig. 1c.  
 
Figure 5: Novel non-coding promoter and enhancer driver candidates. a, RFTN1 
promoter locus (left) and gene expression for mutant (mut.) and wild-type (wt) (right) in 
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Lymph-BNHL tumors. Expression values are colored by copy number status; AID mutations 
are highlighted in yellow. b, A mutational hotspot inside RNF34 overlapping a DNAse I site 
(left) correlates with gene expression changes of KDM2B in Liver-HCC (right). Coloring of 
mutations as in a. c, MTG2 promoter locus (left) and associated gene expression changes in 
Carcinoma tumors (right). Coloring of mutations as in a. d, An enhancer associated with 
TP53TG1 (Methods) (left) contains mutations mostly attributed to an esophageal cancer-
associated signature.  
 
Figure 6: Novel 3’UTR and non-coding RNA driver candidates. a, Quantification of indel 
rates for functional elements associated with significant 3’UTRs. b, Overview of ALB 
genomic locus and PCAWG variants illustrates local density of indels. Coloring of enlarged 
ALB gene elements corresponds to functional elements in barplots in a. Copy number 
changes from 314 Liver-HCC cases are compared to other samples from PCAWG. c, 
Genomic locus of TOB1 3’UTR. Note extreme conservation (PhyloP) for the 3’UTR. d, 
Genomic locus of NFKBIZ 3’UTR (left) and associated gene expression changes in Lymph-
BNHL (right). e, Genomic locus of the RMRP transcript and promoter region (left), and its 
RNA secondary structure, tertiary structure interactions, protein and substrate interactions, 
and mutations with their predicted structural impact (right; Extended Data Figure 9d); 
lymphoma and melanoma are excluded.  
 
Figure 7: Characterization of a mutational process in NEAT1 and MALAT1. a, Genomic 
locus overview showing the distribution of indels and SNVs in NEAT1 and MALAT1. b, 
Analysis of enrichment in LOH associated with mutation (“double-hit”) for canonical tumor 
suppressors (TSG), oncogenes (OG), and NEAT1/MALAT1. c, Comparison of cancer allelic 
fractions within those same genes and within flanking regions (including 2 kbp upstream, 2 
kbp downstream and introns). d, Difference in expression between mutated and wild-type 
alleles of these genes. e, Percentages of different groups of indel sizes for all protein-coding 
and lncRNA genes, ALB, NEAT1, MALAT1 and the set of genes enriched in 2-5 bp indels. f, 
SNV and indel rates (total events/bp) in different functional regions of 18 protein-coding 
genes enriched in 2-5 bps indels (without ALB, which contributed 47% of indels). Red lines 
indicate background indel and SNV rates estimated from all protein-coding genes. 
 
Figure 8: Missed mutations and paucity of non-coding drivers. a, Cumulative 
distribution of average detection sensitivity (d.s.) from 60 PCAWG pilot samples in different 
functional element types. b, Distribution of TERT promoter hotspot (chr5:1295228; hg19) 
detection sensitivity for each each patient, by cohort. Grey dots indicate values for individual 
patients inside estimated distribution (areas colored by cohort). Horizontal black bars mark 
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the medians. Numbers above distributions indicate the percentage of patients powered (d.s. 
≥90%) in each cohort. See Extended Data Fig. 12b for the second TERT hotspot. c, 
Percentage of patients with observed (blue) and inferred missed (red) mutations at the 
chr5:1,295,228 and chr5:1,295,250 TERT promoter hotspot sites. Error bars indicate 95% 
confidence interval. Numbers above bars show the total inferred number of TERT promoter 
mutations for each site in this cohort. Red numbers indicate the absolute number of inferred 
missed mutations (due to lack of read coverage). d, Heatmap shows minimal frequency of a 
driver element in a cohort that is powered (≥90%) to be discovered. Cell numbers indicate 
the number of patients in a given cohort that would need to harbor a mutation in a given 
element. For example, the pan-cancer cohort is powered to discover a driver gene (CDS) 
present in <1% or 18 patients, while the Bladder-TCC cohort is only powered to discover 
drivers present in at least 27% or 6 patients. Power to discover driver elements is dependent 
on the background mutation frequency (shown above the heatmap) and element length 
(shown to the right). e, The ratio between observed numbers of mutations (SNVs and indels) 
in regulatory and coding regions of 142 protein-coding cancer genes. The absolute number 
of driver mutations predicted, with CI95% in brackets, is shown above each bar. 
 
Extended Data Fig. 1: Mutational hotspots in additional tumor types. a, Barplot of 
positions vs. patients. The stacked barcharts under the barplot show the proportion of 
protein-coding (dark grey) and non-coding (light grey) positions, respectively, in each of the 
bars in the barplot. b, Distribution of SNVs in top 50 single-site hotspots across all analyzed 
individual cohorts and meta-cohorts. 
 
Extended Data Fig. 2: Genomic element statistics. a, Percentage of genomic coverage 
for each element type. b, Distribution of element lengths for each element type. 
 
Extended Data Fig. 3: Integration details. a Quantile-quantile plots of p-values reported by 
various driver detection algorithms on the three simulated data sets (Broad, DKFZ, and 
Sanger; shown for coding regions in the meta-carcinoma cohort) showed no major 
enrichment of mutations above the background rate. Results generally followed the expected 
null (uniform) distribution, and the p-values reported on simulated data were subsequently 
used to assess the covariance of method results. b, Quantile-quantile plots of integrated p-
values using the Brown and Fisher methods for combining p-values across the different 
driver detection algorithm results were generated for a few representative tumor cohorts 
(shown here for coding regions). Brown combined p-values (light blue) generally followed the 
null distribution as expected, while Fisher combined p-values were significantly inflated (dark 
blue), confirming that dependencies existed between the results reported by the various 
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driver detection algorithms. To simplify the integration procedure, we calculated covariances 
using p-values from the observed data instead of simulated data and found that the 
integrated results based on the observed covariances (first column of plots) were essentially 
the same as the results obtained using the simulated covariances (second, third, and fourth 
columns of plots). c, Triangular heatmaps showing the Spearman correlations of p-values 
among the various driver detection methods in observed versus simulated data (coding 
regions, meta-carcinoma cohort) are highly similar. Differences in the observed and 
simulated correlation values (shown in the far-right heatmaps) were minimal, and thus the 
final integration of p-values across methods was performed using covariances estimated on 
observed data. d, Integrated p-values based on observed and simulated covariance 
estimations (shown on the right, top heatmap, for coding regions in glioblastoma) did not 
differ noticeably. In cases where individual methods reported results that yielded 
substantially fewer hits than the median across all methods (bottom heatmap, methods in 
light grey with results in dashed box), removing the methods from the integration did not 
affect the number of significant genes identified (right column of results in bottom heatmap, 
shown for coding regions in lung adenocarcinoma). 
 
Extended Data Fig. 4: Sensitivity of driver discovery methods. The performance of 
different driver discovery methods and of the integration method on protein-coding genes 
was evaluated using known cancer genes. A list of 603 Cancer Gene Census genes (CGC, 
v80) was used as a reference gold-standard set of known cancer genes. a-c, For each 
method, genes with q-value<0.10 were sorted according to their p-value and the fraction of 
CGC genes shown in the y-axis. The total number of significant genes identified by each 
method is shown in the x-axis. The integration approach tends to outperform most methods 
across cohorts, yielding longer lists of significant genes and more strongly enriched in known 
cancer genes. d, Heatmap depicting the number of known cancer genes identified by each 
method and by the integration approach in each cohort. The color of each cell reflects the 
relative sensitivity of each method in each cohort, measured as the number of cancer genes 
detected by a method (also shown as a number inside each cell) divided by the maximum 
number detected by any of the methods. Methods are sorted from top to bottom according to 
their mean relative sensitivity across datasets. 
 
Extended Data Fig. 5: Sensitivity vs. specificity in individual cohorts vs. meta cohorts 
for candidate drivers. q-values for the most significant individual cohort (x-axis) vs. meta 
cohort (y-axis) are shown. Driver elements are colored by their element type.  
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Extended Data Fig. 6: Protein-coding driver elements identified in PCAWG cohorts. 
Significant protein-coding elements identified in this study. Compare to figure 4.  
 
Extended Data Fig. 7: Lack of concordance for non-coding results. Heatmaps depicting 
p-values for methods included in integration for Liver-HCC cohorts. a, Most methods agree 
on the top protein-coding hits. b, c: Agreement between methods on non-coding hits is far 
lower for Liver-HCC promoters (b) and 3’UTRs (c).  
 
Extended Data Fig. 8: Mutation to expression correlation. Expression is compared 
between mutated and non-mutated samples. For each element, the z-score of the 
expression values for mutated and wild type in the significant cohort is plotted. For copy 
numbers, SCNA amplification indicates SCNA > 10, SCNA gain indicates SCNA ≥ 3, SCNA 
loss indicates SCNA ≤ 1 and no events indicates SCNA < 3 and SCNA >1. If a patient is 
mutated with multiple point mutation types, indels are indicated over SNVs. 
 
Extended Data Fig. 9: Focal amplifications including TOB1, HES1 and RMRP in TCGA 
tumors. a, Copy number profiles of 55 of 441 stomach adenocarcinomas from TCGA show 
copy number gains around HES1. b, TOB1 and its gene neighbor WIFKKN2 are focally 
amplified in cancer. 172 of 10844 total samples from 33 cancer types are shown. c, RMRP 
focal amplifications in TCGA cancers (160 of 10844 total tumors shown). d, RMRP 
secondary structure (RF00030 in Rfam) labeled with P4 tertiary interactions as well as 
protein and substrate interactions (reported as ± 3bp windows). Mutations and their 
predicted structural impact are indicated. Lymphoma and melanoma mutations are excluded. 
 
Extended Data Fig. 10: Density of potential germline polymorphisms and somatic 
mutations in several candidates. Genomic overviews showing mapping quality masks 
from the 1,000 Genomes Project (pilot/strict), and densities of germline SNP and somatic 
SNV calls on PCAWG normal and tumor samples, respectively. Excess of germline SNP 
calls can be indicative of artifacts, thus an increased number of somatic mutations in such a 
region raises concerns about true mutational recurrence. a, WDR74 promoter, U2 RNA 
element. b, TMEM107 3’UTR. c, RNU12 small RNA. d, RMRP promoter and ncRNA 
transcript. e, RPPH1 ncRNA. f, Genomic overview showing SNVs in mir-142. SNVs 
attributed to the AID mutational signature are marked in orange. 
 
Extended Data Fig. 11: Supporting information for NEAT1 and MALAT1. a, Mutation 
density in the NEAT1 and MALAT1 genomic loci. Co-localized peaks of densities in the loci 
are seen for structural variants, SNVs and indels. b, Levels of expression of the genes 
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enriched in 2-5 bp indels in their respective tissues. Background gene expression levels are 
shown to the left for comparison. c, Heatmap showing the levels of expression across 
tissues for the genes enriched in 2-5 bp indels. d, The average cancer allelic fraction (CAF) 
is compared between each genomic element and the corresponding flanking regions (+/- 
2Kb and introns; overlapping coding exons were excluded). The size of the points represent 
the number of mutated samples for each particular element. e, The relative rate of loss of 
heterozygosity (LOH) is compared between mutated and wild-type samples, coloured by 
element type and highlighting significant LOH enrichments with an outside black circle. f, 
Expression comparison between mutated and wild-type samples. For each element, the 
median log2 fold expression difference of cohorts found significant in the driver discovery is 
plotted. If elements were significant in multiple cohorts, the one with the most significant 
expression difference is shown. Number of mutated samples refers to tumors for which 
RNA-seq data could be obtained. Element types are colored as indicated in the legend. 
Elements with a significant expression difference (q < 0.1 or q < 0.01) are indicated by 
circles. g, Number samples with structural variants (SV) near or in each element is plotted 
against the number of patients with a point mutation. Number of SVs is the sum of event 
counts in bins of 50 kb regions that overlap with a given element. Elements with a 
significantly higher than expected number of samples with SVs are indicated with black 
circles (q < 0.1). 
 
Extended Data Fig. 12: Lack of detection power in specific elements. a, Cumulative 
Average d.s. for selected elements across 60 patients. Exon 3 of the colon cancer gene 
TCF7L2 is 90% powered in only 14/60 (23%) of patients. The TERT promoter and 5’UTR 
element of AKT1 show lack of detection power in the majority of patients. b, Distribution of 
TERT promoter hotspot (chr5:1295250; hg19) detection sensitivity for each each patient, by 
cohort. Grey dots indicate values for individual patients inside estimated distribution (areas 
colored by cohort). Horizontal black bars mark the medians. Numbers above distributions 
indicate the percentage of patients powered (d.s. ≥90%) in each cohort. 
c, Left: distribution (pink) of detection sensitivity across all breast cancer patients (Breast-
AdenoCa, Breast-LobularCa, Breast-DCIS; grey dots) at the FOXA1 promoter hotspot site 
(chr14:38064406; hg19). The number above the distribution plot indicates the percentage of 
patients powered (d.s. ≥90%). Black horizontal bar indicates the median of the distribution. 
Right: percentage of patients with observed (blue) and inferred missed (red) mutations. Error 
bar indicates 95% confidence interval. 
 
Supplementary Tables 
Supplementary Table 1: Genomic element type summary statistics 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
27 
Supplementary Table 2: Driver discovery method description 
Supplementary Table 3: Driver discovery methods included in integration 
Supplementary Table 4: Summary and annotation of protein-coding driver candidates 
Supplementary Table 5: Summary and annotation of non-coding driver candidates 
Supplementary Table 6: Summary of additional evidence for non-coding driver candidates 
Supplementary Table 7: List of cancer genes used in this study 
Supplementary Table 8: List of cases used in detection sensitivity analysis 
Supplementary Table 9: Impact of covariates on obs/exp ratio 
Supplementary Note 
 
  
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
28 
References 
1. Khurana, E. et al. Integrative annotation of variants from 1092 humans: application to 
cancer genomics. Science 342, 1235587 (2013). 
2. Fredriksson, N. J., Ny, L., Nilsson, J. A. & Larsson, E. Systematic analysis of noncoding 
somatic mutations and gene expression alterations across 14 tumor types. Nat. Genet. 
46, 1258–1263 (2014). 
3. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-
genome sequences. Nature 534, 47–54 (2016). 
4. Melton, C., Reuter, J. A., Spacek, D. V. & Snyder, M. Recurrent somatic mutations in 
regulatory regions of human cancer genomes. Nat. Genet. 47, 710–716 (2015). 
5. Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. 
Nature 526, 519–524 (2015). 
6. Northcott, P. A. et al. Enhancer hijacking activates GFI1 family oncogenes in 
medulloblastoma. Nature 511, 428–434 (2014). 
7. Weinhold, N., Jacobsen, A., Schultz, N., Sander, C. & Lee, W. Genome-wide analysis of 
noncoding regulatory mutations in cancer. Nat. Genet. 46, 1160–1165 (2014). 
8. Imielinski, M., Guo, G. & Meyerson, M. Insertions and Deletions Target Lineage-
Defining Genes in Human Cancers. Cell 168, 460–472.e14 (2017). 
9. Rheinbay, E. et al. Recurrent and functional regulatory mutations in breast cancer. 
Nature (2017). doi:10.1038/nature22992 
10. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. 
Science 339, 957–959 (2013). 
11. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 
339, 959–961 (2013). 
12. Flavahan, W. A. et al. Insulator dysfunction and oncogene activation in IDH mutant 
gliomas. Nature 529, 110–114 (2016). 
13. Huarte, M. The emerging role of lncRNAs in cancer. Nat. Med. 21, 1253–1261 (2015). 
14. Bhan, A., Soleimani, M. & Mandal, S. S. Long Noncoding RNA and Cancer: A New 
Paradigm. Cancer Res. 77, 3965–3981 (2017). 
15. Lanzós, A. et al. Discovery of Cancer Driver Long Noncoding RNAs across 1112 
Tumour Genomes: New Candidates and Distinguishing Features. Sci. Rep. 7, 41544 
(2017). 
16. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of 
adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013). 
17. Campbell, P. J. et al. Pan-cancer analysis of whole genomes. (2017). 
doi:10.1101/162784 
18. Perera, D. et al. Differential DNA repair underlies mutation hotspots at active promoters 
in cancer genomes. Nature 532, 259–263 (2016). 
19. Sabarinathan, R., Mularoni, L., Deu-Pons, J., Gonzalez-Perez, A. & López-Bigas, N. 
Nucleotide excision repair is impaired by binding of transcription factors to DNA. Nature 
532, 264–267 (2016). 
20. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase 
inhibition. Nature 486, 353–360 (2012). 
21. Brown, M. B. 400: A Method for Combining Non-Independent, One-Sided Tests of 
Significance. Biometrics 31, 987 (1975). 
22. Fisher, R. A. Statistical Methods For Research Workers. (Genesis Publishing Pvt Ltd, 
1925). 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
29 
23. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 
289–300 (1995). 
24. Pasqualucci, L. et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-
cell lymphomas. Nature 412, 341–346 (2001). 
25. Forbes, S. A. et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a 
resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, 
D652–7 (2010). 
26. Saeki, K. The B cell-specific major raft protein, Raftlin, is necessary for the integrity of 
lipid raft and BCR signal transduction. EMBO J. 22, 3015–3026 (2003). 
27. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the 
human genome. Nature 489, 57–74 (2012). 
28. Kotani, T., Akabane, S., Takeyasu, K., Ueda, T. & Takeuchi, N. Human G-proteins, 
ObgH1 and Mtg1, associate with the large mitochondrial ribosome subunit and are 
involved in translation and assembly of respiratory complexes. Nucleic Acids Res. 41, 
3713–3722 (2013). 
29. Kopan, R. & Ilagan, M. X. G. The canonical Notch signaling pathway: unfolding the 
activation mechanism. Cell 137, 216–233 (2009). 
30. Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal 
adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. 
Genet. 45, 478–486 (2013). 
31. Diaz-Lagares, A. et al. Epigenetic inactivation of the p53-induced long noncoding RNA 
TP53 target 1 in human cancer. Proc. Natl. Acad. Sci. U. S. A. 113, E7535–E7544 
(2016). 
32. Li, B.-S. et al. MicroRNA-25 promotes gastric cancer migration, invasion and 
proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor 
survival. Oncogene 34, 2556–2565 (2015). 
33. Hosoda, N. et al. Anti-proliferative protein Tob negatively regulates CPEB3 target by 
recruiting Caf1 deadenylase. EMBO J. 30, 1311–1323 (2011). 
34. Morin, R. D. et al. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell 
Lymphomas. Clin. Cancer Res. 22, 2290–2300 (2016). 
35. Chapuy, B. et al. Targetable genetic features of primary testicular and primary central 
nervous system lymphomas. Blood 127, 869–881 (2016). 
36. Shadel, G. S. & Clayton, D. A. Mitochondrial DNA maintenance in vertebrates. Annu. 
Rev. Biochem. 66, 409–435 (1997). 
37. Schmitt, M. E. & Clayton, D. A. Nuclear RNase MRP is required for correct processing 
of pre-5.8S rRNA in Saccharomyces cerevisiae. Mol. Cell. Biol. 13, 7935–7941 (1993). 
38. Gill, T., Cai, T., Aulds, J., Wierzbicki, S. & Schmitt, M. E. RNase MRP cleaves the CLB2 
mRNA to promote cell cycle progression: novel method of mRNA degradation. Mol. Cell. 
Biol. 24, 945–953 (2004). 
39. Esakova, O. & Krasilnikov, A. S. Of proteins and RNA: the RNase P/MRP family. RNA 
16, 1725–1747 (2010). 
40. Sabarinathan R, E. al. RNAsnp: efficient detection of local RNA secondary structure 
changes induced by SNPs. - PubMed - NCBI. Available at: 
https://www.ncbi.nlm.nih.gov/pubmed/23315997. (Accessed: 7th July 2017) 
41. Mularoni, L., Sabarinathan, R., Deu-Pons, J., Gonzalez-Perez, A. & López-Bigas, N. 
OncodriveFML: a general framework to identify coding and non-coding regions with 
cancer driver mutations. Genome Biol. 17, 128 (2016). 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
30 
42. Robbiani, D. F. et al. AID produces DNA double-strand breaks in non-Ig genes and 
mature B cell lymphomas with reciprocal chromosome translocations. Mol. Cell 36, 631–
641 (2009). 
43. Fujimoto, A. et al. Whole-genome mutational landscape and characterization of 
noncoding and structural mutations in liver cancer. Nat. Genet. 48, 500–509 (2016). 
44. Lippert, M. J. et al. Role for topoisomerase 1 in transcription-associated mutagenesis in 
yeast. Proc. Natl. Acad. Sci. U. S. A. 108, 698–703 (2011). 
45. Sankar, T. S., Wastuwidyaningtyas, B. D., Dong, Y., Lewis, S. A. & Wang, J. D. The 
nature of mutations induced by replication–transcription collisions. Nature 535, 178–181 
(2016). 
46. Jinks-Robertson, S. & Bhagwat, A. S. Transcription-associated mutagenesis. Annu. 
Rev. Genet. 48, 341–359 (2014). 
47. Ke, H. et al. NEAT1 is Required for Survival of Breast Cancer Cells Through FUS and 
miR-548. Gene Regul. Syst. Bio. 10, 11–17 (2016). 
48. Han, Y., Liu, Y., Nie, L., Gui, Y. & Cai, Z. Inducing Cell Proliferation Inhibition, 
Apoptosis, and Motility Reduction by Silencing Long Noncoding Ribonucleic Acid 
Metastasis-associated Lung Adenocarcinoma Transcript 1 in Urothelial Carcinoma of 
the Bladder. Urology 81, 209.e1–209.e7 (2013). 
49. Dabney, J. & Meyer, M. Length and GC-biases during sequencing library amplification: 
a comparison of various polymerase-buffer systems with ancient and modern DNA 
sequencing libraries. Biotechniques 52, 87–94 (2012). 
50. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 
tumour types. Nature 505, 495–501 (2014). 
51. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and 
heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013). 
52. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. 
Nat. Biotechnol. 30, 413–421 (2012). 
53. Martincorena, I. et al. Universal Patterns of Selection in Cancer and Somatic Tissues. 
Cell (2017). doi:10.1016/j.cell.2017.09.042 
54. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new 
cancer-associated genes. Nature 499, 214–218 (2013). 
55. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-
wide association summary statistics. Nat. Genet. 47, 1228–1235 (2015). 
56. Perera, D. et al. Differential DNA repair underlies mutation hotspots at active promoters 
in cancer genomes. Nature 532, 259–263 (2016). 
57. Sabarinathan, R., Mularoni, L., Deu-Pons, J., Gonzalez-Perez, A. & López-Bigas, N. 
Nucleotide excision repair is impaired by binding of transcription factors to DNA. Nature 
532, 264–267 (2016). 
58. Flavahan, W. A. et al. Insulator dysfunction and oncogene activation in IDH mutant 
gliomas. Nature 529, 110–114 (2016). 
59. Hnisz, D. et al. Activation of proto-oncogenes by disruption of chromosome 
neighborhoods. Science 351, 1454–1458 (2016). 
 
 
 
 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
31 
Methods 
Table of contents: 
1. Patient cohorts 
2. Mutational hotspot analysis 
3. Mutational signatures 
4. Genomic element definition 
5. Driver discovery methods 
6. Simulated data sets 
7. Statistical framework for the integration of results from multiple driver discovery 
methods 
8. Post-filtering of candidates 
9. Sensitivity and specificity analysis 
10. Gene expression analyses 
11. Normalization for copy number variation 
12. Mutation to expression association 
13. Copy number analyses 
14. Power analysis 
15. Associations between mutation and signatures of selection: loss of heterozygosity 
and cancer allelic fractions 
16. Signals of selection in aggregates of non-coding regions of known cancer genes 
17. Mutational process and indel enrichment 
18. Mutation association with splicing 
19. Structural variation analysis 
20. RNA structural analysis 
21. Cancer associated germline variant distance to non-coding driver candidates 
 
  
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
32 
 
1. Patient cohorts 
Generation of high-quality tumor set (Loris Mularoni) 
We selected a total of 2583 samples to be included in the driver detection analyses. This list 
contains all the samples that were not flagged as problematic by the PCAWG-TECH group. 
A single aliquot was assigned to each sample; in cases where multiple aliquots were 
present, we selected a single aliquot based on the following criteria, in order of importance:  
- we prioritized primary tumors over metastatic or recurrent tumors  
- we selected aliquots with an OxoG score higher than 40 
- we prioritized aliquots with the highest quality (as indicated by the Stars values) 
- we prioritized aliquots with RNA-seq data availability 
- we prioritized aliquots with the lowest contamination (as indicated by the ContEst values) 
- if a selection could not be made after applying the above filters we selected an aliquot 
randomly 
 
Selection of tumor cohorts for analysis (Esther Rheinbay) 
Individual tumor type cohorts from the high-quality tumor set were selected for analysis if 
they met a minimum size. This size was determined based on the cumulative number of 
patients, such that no more than 2.5% of total patients were excluded. This led to a minimum 
cohort size criterion of 20 patients, and removed the Bone-Cart (9 donors), Bone-Epith (11), 
Bone-Osteoblast (5), Breast-DCIS (3), Breast-LobularCa (13), Cervix-AdenoCa (2), Cervix-
SCC (18), CNS-Oligo (18), Lymph-NOS (2), Myeloid-AML (13) and Myeloid-MDS (2) 
individual cohorts. Samples from these cohorts were still included in meta-cohort analysis 
(see below). 
 
Tumor meta-cohorts (Esther Rheinbay) 
Tumor meta-cohorts were assembled for identification of drivers and increase of discovery 
power across cell lineages and organ systems. The following meta cohorts were used in 
driver analyses: 
By cell type of origin: 
Epithelial: Carcinoma (comprised of tumor cohorts Bladder-TCC, Biliary-AdenoCa, 
Breast-AdenoCa, Breast-LobularCa, Cervix-AdenoCa, ColoRect-AdenoCa, Eso-
AdenoCa, Kidney-ChRCC, Kidney-RCC, Liver-HCC, Lung-AdenoCa, Ovary-
AdenoCa, Panc-AdenoCa, Panc-Endocrine, Prost-AdenoCa, Stomach-AdenoCa, 
Thy-AdenoCa, Uterus-AdenoCa,Head-SCC, Cervix-SCC, Lung-SCC), 
Adenocarcinoma (Biliary-AdenoCa, Breast-AdenoCa, Breast-LobularCa, Cervix-
AdenoCa, ColoRect-AdenoCa, Eso-AdenoCa, Kidney-ChRCC, Kidney-RCC, Liver-
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HCC, Lung-AdenoCa, Ovary-AdenoCa, Panc-AdenoCa, Prost-AdenoCa, Stomach-
AdenoCa, Thy-AdenoCa, Uterus-AdenoCa), squamous epithelium (Head-SCC, 
Cervix-SCC, Lung-SCC) 
Mesenchymal cells/sarcoma (Bone-Cart, Bone-Epith, Bone-Leiomyo, Bone-
Osteosarc) 
Glioma (CNS-PiloAstro, CNS-Oligo, CNS-GBM) 
Hematopoietic system (Lymph-BNHL, Lymph-CLL, Lymph-NOS, Myeloid-AML, 
Myeloid-MDS, Myeloid-MPN) 
By organ system:  
digestive tract (Liver-HCC, ColoRect-AdenoCa, Panc-AdenoCa, Eso-AdenoCa, 
Stomach-AdenoCa, Biliary-AdenoCa), kidney (Kidney-RCC, Kidney-ChRCC), lung 
(Lung-AdenoCa, Lung-SCC), lymphatic system (Lymph-BNHL, Lymph-CLL, 
Lymph-NOS), myeloid (Myeloid-AML, Myeloid-MDS, Myeloid-MPN), breast (Breast-
AdenoCa, Breast-LobularCa), female_reproductive_system (Breast-AdenoCa, 
Breast-LobularCa, Cervix-AdenoCa, Cervix-SCC, Ovary-AdenoCa, Uterus-
AdenoCa), central nervous system (CNS-PiloAstro, CNS-Oligo, CNS-Medullo, 
CNS-GBM) 
Pan-cancer:  
 Two “Pan-cancer” cohorts were created: “Pancan-no-skin-melanoma” containing all 
tumor types with the exception of Skin-Melanoma to remove issues caused by very high 
mutation rate tumors; and “Pancan-no-skin-melanoma-lymph” with the additional removal of 
lymphoid tumors (Lymph-BNHL, Lymph-CLL, Lymph-NOS) that have local somatic 
hypermutation caused by AID. 
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2. Mutational hotspot analysis (Randi Istrup Pedersen) 
We selected the top 50 single position hotspots based on the number of patients with an 
SNV mutation. The individual positions marked as problematic by the site-specific noise filter 
(see below) analysis were excluded. 
 
Each hotspot was defined by its genomic position and annotated by the number of patients 
with an SNV mutation in the given hotspot. We also annotated each hotspot with whether it 
falled in one of the genomic element types analyzed in the driver discovery. We further 
overlapped with loop-regions of palindromes, which are hypothesized to fold into DNA-level 
hairpins, and with location in immunoglobulin loci. When a hotspot overlapped a protein-
coding gene we extracted the corresponding amino acids changes from Oncotator1 
(http://portals.broadinstitute.org/oncotator/). 
 
We identified known driver hotspots, by overlap with the somatic driver positions compiled in 
the Cancer Genome Interpreter repository 
(https://www.cancergenomeinterpreter.org/mutations), which among others include 
mutations from ClinVar, DoCM and the literature (ref: https://doi.org/10.1101/140475). 
 
For each hotspot we calculated the proportion of mutations in the defined cohorts and meta-
cohorts. Only cohorts with at least 20 patients, and at least 10 patients or 10% of patients 
with an SNV were included in Fig. 1a (for the distribution in all cohorts and meta-cohorts see 
Extended Data Fig. 1). Lymph-BNHL and Lymph-CLL were shown together as Lymphoid 
malignancies. 
 
Based on mutational signature analysis of all the cancer samples, we extracted the posterior 
probability that each hotspot mutation from a given patient was generated by one of 37 
identified mutational signatures. In lymphoid malignancies somatic hyper-mutations 
generated by AID come in clusters along the genome. Posterior probabilities for the ten 
signatures relevant for the lymph cohorts were therefore derived from models that consider 
the correlation of AID mutations along the genome. For each hotspot the collected posterior 
probabilities were averaged. 
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3. Mutational Signatures (Jaegil Kim) 
We performed a de novo global signature discovery to identify mutational signatures 
operating in PCAWG WGS cohort (N = 2,583). All single nucleotide variants (SNVs) were 
stratified into M = 4608 mutation channels according to the combination of six base 
substitutions at pyrimidine bases (C>A/G/T and T>A/C/G) in penta-nucleotide sequence 
contexts and a transcription strand direction, transcribed (-), non-transcribed (+), non-coding 
regions. All insertions and deletions were classified into additional 20 channels depending on 
the number of inserted or deleted bases and any indels beyond 9 bases were grouped into a 
single channel. The resulting mutation frequency matrix X (4,628 channels across 2,583 
samples) were ingested to the Broad Institute’s signature analysis pipeline, 
SignatureAnalyzer, to determine the optimal number of signatures (K) and the signature 
profiles by de-convoluting X into a product of two non-negative matrices as X ~ WH, W (M × 
K) and H (K × N) being a signature-loading and an activity-loading matrix, respectively. The 
most distinguished feature of SignatureAnalyzer is that it suggests an optimal number of 
signatures best explaining X at the balance between the error measure and the model 
complexity exploiting Bayesian non-negative matrix algorithm (NMF)2,3,4. Our de-novo 
signature discovery identified 37 signatures including a split of 4 UV-related signatures, 3 
APOBEC-related signatures, 5 POLE-related signatures, 3 MSI-related signatures, 2 
COSMIC17 signatures, and other 21 singleton signatures (see PCAWG7 paper for details). 
  
Although the matrix H contains the most representative activity across samples it also has 
spurious activity assignments intrinsic to the global signature discovery (i.e., applying 
SignatureAnalyzer on samples with different histological subtypes and mutational 
processes).  To minimize this contamination and interference we re-assigned activity 
separately in each histological subtype using a more refined projection approach. We first 
identified a subset of ultra-mutant samples with a dominant activity of POLE (n = 8), MSI (n = 
18), and alkylating signatures (n = 1) from the original H, which are usually very exclusive to 
samples with a specific DNA repair or replication defect, or a treatment. To prevent a false-
positive assignment of these signatures in remaining samples we introduced a binary matrix 
Z (37 × N), where the row elements corresponding to POLE, MSI, and alkylating signatures, 
are set to zero except for samples with a dominant activity, while all other elements are set 
to one. More specifically, the projection was done by keeping the signature-loading matrix W' 
(M × 37) frozen  (W' represents the normalized signature profiles of 37 global signatures), 
while allowing SignatureAnalyzer to determine a subset of signatures and infer the activity-
loading matrix H' (37 × N') that best approximates the mutation frequency matrix X' (M × N'), 
where N' represents the number of samples in each histological subtype, as X' ~ W' (Z'¤H'), 
Here “¤” denotes element-wise multiplications.  
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4. Definition of genomic elements (Morten Muhlig Nielsen; Nicholas Sinnott-Armstrong) 
For coding elements and elements pertaining to protein coding genes (3’UTR, 5’UTR and 
protein coding promoters) regions were defined based on GENCODE annotations (v.19)5: 
 
Coding elements (CDS): The set of coding bases collapsed across all coding transcripts 
with a given GENCODE gene ID.  
 
Protein coding splice site elements (pcSS): Intronic regions extending 6 bases from 
donor splice sites and 20 bases from acceptor splice sites were collected for all coding 
transcripts. Bases were collapsed across all coding transcripts with a given GENCODE gene 
ID. The global set of CDS bases were subtracted.  
 
5’UTR elements (5UTR): The set of 5’UTR bases collapsed across all coding transcripts 
with a given GENCODE gene ID. The global set of CDS and pcSS bases were subtracted.  
 
3’UTR elements (3UTR): The set of 3’UTR bases collapsed across all coding transcripts 
with a given GENCODE gene ID. The global set of CDS, pcSS and 5UTR bases were 
subtracted.  
 
Protein coding promoter elements (pcPROM): Regions extending 200 bases in both 
directions from all protein coding transcripts’ transcription start sites (5’ ends). Bases were 
collapsed across all coding transcripts with a given GENCODE gene ID. The global set of 
CDS and pcSS bases were subtracted.  
 
lncRNA elements: lncRNA transcripts were defined based on annotations from GENCODE 
(v.19) and MiTranscriptome (v.2)6 not overlapping GENCODE. Transcripts were included if 
fulfilling criteria 1-5 and 6 or 7 below: 
1) No sense overlap to protein coding gene regions 
2) More than 5kb away from protein coding genes on sense strand. 
3) Longer than 200 bases. 
4) Not annotated as the following biotypes: immunoglobulin, T-cell receptor, Mt_rRNA, 
Mt_tRNA, miRNA, misc_RNA, rRNA, scRNA, snRNA, snoRNA, ribozyme, sRNA or 
scaRNA. 
5) Not overlapping genomic regions aligning back to the human genome (self chained 
regions). 
6) More than 20% of bases overlap conserved elements (except if annotated as 
pseudogene) 
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7) Expressed in more than 10% of PCAWG samples with RNAseq data. 
 
Genes corresponding to the selected transcripts were supplemented with a set of known 
functional lncRNA genes from the literature in addition to GENCODE annotated non-coding 
snoRNA and miRNA host genes. The elements were made by collapsing bases across 
transcripts with given gene ID. The global set of CDS, pc_SS, 5UTR, 3UTR, pcPROM and 
lncRNA_SS bases were subtracted. 
 
lncRNA splice site elements (lncRNASS): Intronic regions extending 6 bases from donor 
splice sites and 20 bases from acceptor splice sites were collected for all lncRNA transcripts. 
Bases were collapsed across all lncRNA transcripts with a given gene ID. The global set of 
CDS, pc_SS, 5UTR, 3UTR and pcPROM bases were subtracted. 
 
lncRNA promoter elements: Regions extending 200 bases in both directions from all 
lncRNA transcripts’ transcription start sites (5’ends). Bases were collapsed across all 
lncRNA transcripts with a given gene ID. The global set of CDS, pc_SS, 5UTR, 3UTR, 
pcPROM and lncRNA_SS bases were subtracted. 
 
Short RNA elements: Short RNA transcripts were defined based on annotations from 
databases Rfam (v.11)7, tRNAscanSE (v.2.0)8 and snoRNAdb (v.3)9 in addition to 
GENCODE transcripts with biotype annotations mt_rRNA, mt_tRNA, misc_RNA, rRNA and 
snoRNA. 
Bases were collapsed across all smallRNA transcripts with a given gene ID. The global set 
of CDS, pc_SS, 5UTR, 3UTR and pcPROM bases were subtracted. 
 
microRNA elements: Mature miRNAs were defined based on mirBase (v.20)10 and a set of 
potential novel miRNAs11  
 
Enhancers: Contiguous 15-state ChromHMM called enhancers correlated between 
H3K4me1 and RNA-seq across 57 human tissues were downloaded from Roadmap 
Epigenomics Consortium extended data12. Associated links, defined by co-occurring activity 
in a given cell type, were merged across cell types at FDR = 0.1. HoneyBadger213 p10 calls 
for all DNase I sites were filtered to peaks with signal strength 0.8 or greater and intersected 
with enhancer elements. The union of all DNase I peaks which overlapped with a given 
element, with all CDS regions filtered out, were used as the input to driver detection. 
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5. Candidate driver identification methods 
A summary of approaches used by each method is listed in Supplementary Table 2. 
ActiveDriverWGS (Juri Reimand)  
Driver analysis with ActiveDriverWGS (ref) was performed after discarding hypermutated 
samples (>90,000 mutations) from the PCAWG cancer cohort.To avoid leakage of signals 
from known cancer drivers, we removed missense mutations in analyses of non-coding 
regions. ActiveDriverWGS is a local mutation enrichment method for genome-wide discovery 
of cancer driver mutations with increased mutation burden of single nucleotide variants 
(SNVs) and indels. ActiveDriverWGS performs a model-based test whether a given genomic 
element is significantly more mutated than adjacent background genomic sequence (+/- 
10kb and introns). Statistical significance of mutations is computed with a Poisson-linked 
generalised linear regression model. The null model treats all SNVs with trinucleotide 
context as cofactor, while indels are modelled with a separate cofactor for all nucleotides. 
Mutation counts per nucleotide are presented as the response variable The alternative 
model tests whether the element has different mutation burden than the background 
sequence. The null and alternative models are compared with chi-square tests and 
confidence intervals of expected mutations were derived from the null model using 
resampling. If the confidence intervals indicated significant excess of mutation in the 
background and depletion in the element of interest, we inverted corresponding small p-
values (p=1-p if p<0.5). Elements with no mutations were automatically assigned p=1.  
 
CompositeDriver0.2 (Eric Minwei Liu, Ekta Khurana) 
We have developed CompositeDriver (ref) – a computational method that combines signals 
of mutation recurrence and the functional impact score derived from FunSeq2 scheme14 to 
identify coding and non-coding elements under positive selection. CompositeDriver assigns 
a score to each region of interest (i.e., CDS, promoter, UTR, enhancer or ncRNA) through 
summation of positional mutation recurrence multiplied by the functional impact score for all 
mutations within the region. A null CompositeDriver score distribution is built to calculate the 
p-value for a region of interest. Mutations in the same element type but outside the region of 
interest are defined as background mutations. To build the null distribution, the same 
numbers of mutated positions are repeatedly drawn (default is 105 times) from background 
mutations with similar replication timing and similar mutation context15. By drawing random 
mutations from the same element type, CompositeDriver incorporates DNase I 
hypersensitive sites and histone modification marks as covariates into the null model16. 
Finally, the Benjamini-Hochberg method is used for multiple hypothesis correction17. 
 
dNdScv (Inigo Martincorena) 
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dNdScv is a maximum-likelihood algorithm designed to test for positive or negative selection 
in cancer genomes or other sparse resequencing studies. dNdScv models somatic 
mutations in a given gene as a Poisson process, accounting for sequence composition and 
mutational signatures using 192 trinucleotide substitution rates. Mutation rates are also 
known to vary across genes, often co-varying with functional features of the human genome, 
such as replication time and chromatin state. This information is exploited by dNdScv to 
refine the estimates of the background mutation rate of each gene, using a negative 
binomial regression. This regression removes known sources of variation of the mutation 
rates and models the remaining unexplained variation of the mutation rate across genes as 
being Gamma distributed, which protects the method against overconfidence in the 
estimated background mutation rate for a gene. Overall, the local mutation rate for a gene is 
estimated accounting for mutational signatures in the samples analysed, the sequence 
composition of a gene in a trinucleotide context, 20 epigenomic covariates and the local 
number of synonymous mutations in the gene. Inferences on selection are carried out 
separately for missense substitutions, truncating substitutions (nonsense and essential 
splice site mutations) and indels, and then combined into a global P-value per gene. dNdScv 
has been described in much greater detail elsewhere18. 
 
DriverPower (Shimin Shuai) 
DriverPower is a combined burden and functional impact test for coding and non-coding 
cancer driver elements. In the DriverPower framework, randomized non-coding genome 
elements are used as training set. In total 1373 reference features covering nucleotide 
compositions, conservation, replication timing, expression levels, epigenomic marks and 
compartments are collected for downstream modelling. For the modelling, a feature selection 
step by randomized Lasso is performed at first. Then the expected background mutation rate 
is estimated with selected highly important features by binomial generalized linear model. 
The predicted mutation rate is further calibrated with functional impact scores measured by 
CADD and Eigen scores. Finally, a p-value is generated for each test element by binomial 
test with the alternative hypothesis that the observed mutation rate is higher than the 
adjusted mutation rate. 
 
ExInAtor (Andres Lanzos; Rory Johnson) 
ExInAtor was specifically created for prediction of cancer driver lncRNAs, but is agnostic to 
gene type and can also be used for protein-coding genes. The exons of each gene are 
identified and collapsed across transcript isoforms. For each gene, the trinucleotide content 
of the exonic region is calculated. The remaining intronic regions, along with 10 kb of 
sequence upstream and downstream, are defined as the background region. From this 
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background, a new background region is created by randomly sampling the maximum 
number of nucleotides, such that the trinucleotide content exactly matches that of the exonic 
region. Next, the number of mutations in the exonic and sampled background regions are 
compared by hypergeometric test. Genes with elevated exonic mutational density are 
considered candidate driver genes. ExInAtor was used with randomisation seed of 256. 
Otherwise ExInAtor was run exactly as described in Lanzós et al, 201719. 
 
LARVA (Jing Zhang; Lucas Lochovsky) 
LARVA20, or Large-scale Analysis of Recurrent Variants in noncoding Annotations, is a 
computational method that detects significantly elevated somatic mutation burdens in 
genomic elements—both coding and non-coding—to identify putative cancer-driving 
elements. Given a cancer cohort variant call set, and a list of genomic elements, LARVA 
models the expected background somatic mutation rate by fitting a beta-binomial distribution 
to the elements' variant counts. This model properly accounts for the high mutation rate 
variability seen throughout the genome, which improves over some previous models' 
assumption of a constant mutation rate. LARVA's model also incorporates the influence of 
mutation rate covariates, such as DNA replication timing. LARVA's output lists each genomic 
element from the input, along with a p-value based on the deviation of the element's 
observed variant count from the expected variant count under LARVA's model. 
 
MutSig (Julian Hess, Esther Rheinbay) 
The MutSig suite21 classifies whether genomics features, both coding and non-coding, are 
highly mutated relative to a predicted background mutation rate (BMR), which varies on a 
macroscopic-level across patients (patient-specific mutation rates can span orders of 
magnitude across pan-cancer cohorts) and genes (known covariates such as replication 
timing are strongly correlated with mutation rate) and on a microscopic level across 
sequence contexts (since mutational signatures are heterogeneous across a cohort and 
highly context-dependent). MutSig accounts for all three of these to compute the joint BMR 
distribution across genes/patients/contexts, and then convolves across the latter two 
dimensions to estimate the expected distribution of total background burden for a given gene 
across a whole cohort. Genes are then scored by how their total non-background burden 
exceeds this null distribution. 
 
MutSig estimates a gene’s BMR by its synonymous mutation rate for coding genes, and by 
its mutation rate at nonconserved positions for non-coding genes. If the number of 
background mutations in a given gene is insufficient to provide a confident estimate of its 
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BMR, MutSig will incorporate the background counts from other genes with similar covariate 
profiles into its estimator. 
 
MutSig (MutSig2CV) was originally designed for coding regions only21. Modifications to this 
version of the algorithm to run on non-coding regions are novel to PCAWG. Coding MutSig 
also incorporates per-gene functional impact and clustering tests, which were not run on 
non-coding regions. 
 
NBR (Inigo Martincorena) 
NBR is a method that test for evidence of higher mutation density than expected by chance 
in a given region of the genome, while accounting for trinucleotide mutational signatures, 
sequence composition and the local density of mutations around each element. This method 
has been described in detail in a previous publication22, where it was used to identify 
candidate driver noncoding elements across 560 breast cancer whole-genomes. 
  
Based on some of the features of dNdScv, NBR involves two main steps. First, all mutations 
across all elements tested are used to obtain maximum-likelihood estimates for the 192 rate 
parameters (rj) describing each of the possible trinucleotide substitutions in a strand-specific 
manner. rj = nj/Lj , where nj is the total number of mutations observed across samples of a 
given trinucleotide class (j) and Lj is the number of available sites for each trinucleotide. 
These rates are used to estimate the total number of mutations across samples expected 
under neutrality in each element considering the mutational signatures active in the cohort 
and the sequence of the elements (Eh = Sj rjLj,h). This estimate assumes no variation of the 
mutation rate across elements in the genome. Second, a negative binomial regression is 
used to refine this estimate of the background mutation rate of an element, using covariates 
and Eh as an offset. In this study, the local density of somatic mutations (normalized by 
sequence composition) was used as a covariate, using a window around the element of a 
variable size across cohorts to ensure sufficient numbers of mutations in each window 
around each element and excluding coding sequences and previously identified candidate 
noncoding driver regions. Replication time and average gene expression level for 100 kb 
genomic bins were also used as covariates. The negative binomial regression models 
mutation counts as Poisson-distributed within an element with mutation rates varying across 
elements according to a Gamma distribution. As in dNdScv, this provides a refined estimate 
of the background mutation rate for each element (Eh*) as well as a data-driven measure of 
uncertainty around this estimate (-q- the overdispersion parameter of the negative binomial 
regression). P-values for each element are calculated using a cumulative negative binomial 
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distribution with the mean (Eh*) and dispersion (q) parameters estimated by the negative 
binomial regression. 
  
To protect against neutral indel hotspots or indel artefacts, unique indel sites rather than total 
indels per element were used. To protect against misannotation of a mutation clusters as 
sets of independent events, a maximum of two mutations per region and per sample were 
considered in the analysis. 
 
ncdDetect (Malene Juul) 
ncdDetect23 is a driver detection method tailored for the non-coding part of the genome. It 
uses a burden based approach, in which the frequency of mutations is considered, to reveal 
signs of recurrent positive selection across cancer genomes. For each candidate region, the 
observed mutation frequency is compared to a sample- and position-specific background 
mutation rate. A scoring scheme is applied to further account for functional impact in the 
significance evaluation of a candidate cancer driver element. In the present application, the 
scoring scheme is defined as log-likelihoods, i.e. minus the natural logarithm of the sample- 
and position-specific probabilities of mutation. 
  
The position- and sample-specific probabilities of mutation used by ncdDetect are obtained 
by a statistical null model, inferred from somatic mutation calls of a collection of cancer 
samples (https://doi.org/10.1101/122879). The model includes a set of genomic annotations, 
known to correlate with the mutation rate in cancer. These are replication timing, 
trinucleotides (the nucleotide under consideration and its left and right flanking bases), 
genomic segment (a variable segmenting the genome into regulatory element types) and a 
position-specific measure of the local mutation rate (a weighted average of the mutation rate, 
calculated across samples in a 40 kb window flanking each specific position plus/minus 10 
kb). 
 
ncDriver (Henrik Hornshøj) 
The ncDriver method (doi: https://doi.org/10.1101/182642) provides separate evaluations 
of the significance for two functional mutation properties, the level of conservation and the 
level of cancer type specificity. In the ncDriverConservation test, the conservation level of 
mutated positions were evaluated locally for being surprisingly high, given the distribution of 
conservation within the element. The p-value of the mean mutation phyloP conservation 
score for an element was obtained by Monte Carlo simulation of 100,000 mean phyloP 
scores based on the same number of mutations. Each mutated element was also evaluated 
globally by looking up the rank of the element mean phyloP conservation score among all 
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elements annotated as the same type. This provided p-values for both local and global 
mutation conservation level, which were combined into a single conservation p-value using 
Fisher’s method. In the ncDriverCancerType test, the distribution of observed mutation 
counts of an element across the cancer types were evaluated for being surprising compared 
to expected counts estimated from a background null model (as described for the ncdDetect 
method) that accounts for cancer type specific mutation signatures and other co-variates. A 
Goodness-of-fit test with Monte Carlo simulation was used to determine whether the 
distribution of observed mutation counts across cancer types within the element is surprising 
given the expected mutation counts based on cancer types, mutation contexts and element 
type. For indels, the expected mutation counts were estimated solely from the mutation rates 
calculated from the mutation context, cancer type and element type. 
 
OncodriveFML (Loris Mularoni) 
OncodriveFML24 is a method designed to estimate the accumulated functional impact bias of 
tumor somatic mutations in genomic regions of interest, both coding and non-coding, based 
on a local simulation of the mutational process affecting it. The rationale behind 
OncodriveFML is that the observation of somatic mutations on a genomic element across 
tumors, whose average impact score is significantly greater than expected for said element 
constitutes a signal that these mutations have undergone positive selection during 
tumorigenesis. This, in turn is considered as a direct indication that this element drives 
tumorigenesis.  
 
OncodriveFML first computes the average functional impact score of the observed mutations 
in the element of interest. The functional impact scores of mutations have been calculated 
using both CADD25 (coding and non-coding regions) and VEST326 (only coding regions). 
Then the method randomly samples the same number of observed mutations following the 
probability of mutation of different tri-nucleotides, computed from the mutations observed in 
each cohort. The randomization step is repeated many times (1,000,000 in these analyses) 
and each time an average functional impact score is calculated. Finally, OncodriveFML 
derives an empirical p-value for each element by comparing the average functional impact 
score observed in the element to its local expected average functional impact score resulting 
from the random sampling. The empirical p-values are then corrected for false discovery rate 
and genomic elements that after the correction are still significant are considered candidate 
drivers. 
 
regDriver (Husen M. Umer) 
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regDriver assesses the significance of mutations affecting transcription factor motifs using 
tissue-specific functional annotations (https://doi.org/10.1002/humu.23014). For each tumor 
cohort, functional annotations from the cell lines most similar to the respective tumor type 
are gathered. A functionality score is computed for each mutation based on its overlapping 
functional annotations. regDriver, collects highly-scored mutations in each of the defined 
elements and assesses the elements’ significance by comparing its accumulative score to a 
background score distribution obtained from the simulated sets. Therefore, only candidate 
regulatory mutations are considered in evaluating mutation enrichment per element.  
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6. Simulated datasets 
 
Broad simulations (Yosef Maruvka, Gad Getz) 
Due to their differing context characteristics, we simulated SNVs and indels with different 
approaches. For SNVs, we divided the genome into 50kb regions. For each region, we 
counted the number of mutations in it across all the PCAWG patients and divided it by the 
total number of mutations. Every mutation was randomly assigned into a new region based 
on the region's rate. The position inside the region was chosen to maintain the trinucleotide 
context of each mutation (the 5’ and 3’ nearest neighbors and the mutated position itself) 
and the alternate allele. In addition, for every base we counted how many times it was 
covered sufficiently, in 401 tumor and normal WGS pairs, in order to enable calling of a 
mutation27. The fraction of patients with enough coverage at a given site was used as the 
position’s probability for being mutated inside the new current region.  
 
For indels, a new, randomized position was chosen in a region of 50,000 bases around the 
indel. The position of the new indel was chosen to match the indel 5’ and 3’ neighboring 
reference bases. For insertions, the inserted motif was the same as the original insertion, but 
for deletions only the length of the indels was kept but not the exact sequence. 
 
DKFZ simulations (Carl Hermann, Calvin Chan) 
This simulation utilizes the SNV calls to perform a localised randomisation. The original SNV 
entries which do not map to chromosome 1-22, X, Y are first filtered and excluded from 
randomization. All SNVs located in the protein coding regions (CDS) corresponding to 
GENCODE19 definition are erased before performing randomisation. The trinucleotide 
centered at each SNV position is determined and an identical trinucleotide is randomly 
sampled within the 50kb window. In case of insertion, instead of the mutated trinucleotide, 
the neighboring nucleotide of the insertion site is scanned within the randomisation window. 
For deletion and multi-nucleotides variants, the altered sequence is scanned within the 
randomization window with a ranked probability assigned for each position. The randomised 
sample is then selected from the top 100 matched positions with scaled probability. 
 
Sanger simulations (Inigo Martincorena) 
This simulation aimed to generate datasets of neutral somatic mutations that retain key 
sources of variation in mutation rates known to exist in cancer genomes, including 
mutational signatures, and variable mutation rates across the genome and among 
individuals and cancer types. To do so while minimizing the number of assumptions in the 
simulation, we used a simple local randomization approach. First, all coding mutations as 
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well as mutations in the TERT promoter, MALAT1 or NEAT1 were excluded. Second, each 
mutation in each patient was randomly moved to an identical trinucleotide within a 50 kb 
window, while retaining the patient ID. Third, mutations falling within 50 bp of their original 
position were filtered out. This simple randomization retains the variation of the mutation rate 
and mutational signatures across large regions of the genome, across individuals and across 
cancer types. 
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7. Statistical framework for the integration of results from multiple driver discovery 
methods (Grace Tiao, Gad Getz) 
The classical approach for combining p-values obtained from independent tests of a given 
null hypothesis was described by R. A. Fisher in 1948. He noted that for a set of k p-values, 
the sum X of the transformed p-values, where 
  
X = -2 Σki=1 ln(pi) 
  
and pi is the p-value for the ith test, follows a chi-square distribution with 2k degrees of 
freedom28. Thus, to obtain a single combined p-value for a set of independent tests, the new 
test statistic X is computed from the p-values obtained from the tests and scored against a 
chi-square distribution with 2k degrees of freedom. Fisher’s test is asymptotically optimal 
among all methods of combining independent tests29; however, in cases where tests exhibit 
dependence, the Fisher combined p-value is generally too small (anti-conservative). 
 In this study, we combine p-values from several driver detection methods, many of 
which share similar approaches and whose results are therefore not independent. To 
address this issue, we used an extension of the Fisher method developed by Morten Brown 
for cases in which there is dependence among a set of tests29. Using the same test statistic, 
renamed Ψ to indicate the difference in the independence assumption, Brown observed that 
if Ψ were assumed to have a scaled chi-square distribution – i.e., 
  
ψ ~ c X22f 
  
then 
  
f = E[ψ]2/var(ψ)  and c = var(ψ)/ 2E[ψ] 
  
  
Note that E[Ψ] = 2k irrespective of the independence requirement, and that 
  
var(ψ) = 4k + 2 Σi<j cov(-2 lnpi, -2 lnpj) 
  
Thus when the pi are independent, var(ψ) = 4k, which gives f = k and c = 1, and the test 
statistic follows the chi-square distribution with 2k degrees of freedom described by Fisher. 
However, when the independence condition is relaxed, var(ψ) ≠ 4k, and the test statistic 
generally follows a different, scaled, chi-square distribution whose scaling parameter c and 
degrees of freedom 2f are determined by the covariances of the pi’s. The covariances can 
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be computed via numerical integration over the joint distributions of all pi and pj pairs, but 
this requires knowledge of the joint distribution; and even in cases where the joint distribution 
is known, the integration may not be computationally feasible for large and complex 
datasets30. 
In this study, following the example of Poole et. al31, we computed the empirical 
covariance of pi and pj, using the samples wi and wj , where wi is the set of all reported p-
values for method i, and used the empirical covariance to approximate the Brown scaled chi-
square distribution. The advantage to this approach is that the empirical covariance 
estimation is non-parametric – it does not assume an underlying joint distribution of pi and pj 
– and is thus applicable to complex and interrelated biological datasets where data is noisy 
and not regularly Gaussian. Poole et. al showed that the empirical covariance estimation 
approach is accurate, robust, and efficient for such datasets. 
  
  
Implementing and evaluating the integration method on simulated and observed data 
To evaluate the efficacy of the empirical Brown’s method of dependent p-value integration, 
we generated three sets of simulated mutation data (see above) and ran the driver detection 
algorithms on each of the simulated datasets. We checked that the p-value results from the 
various driver detection algorithms followed the expected null (uniform) distribution 
(Extended Data Fig. 3a). Then, for each simulated data set, we calculated the empirical 
covariance for each pair of driver algorithm results. We then used these covariance values 
over simulated datasets to compute the combined Brown p-values on observed data: for 
each gene in the observed PCAWG somatic mutation dataset, we computed the Brown test 
statistic from the set of p-values reported by the various driver detection algorithms. The 
Brown test statistic was then evaluated against the appropriate chi-square distribution, 
whose scale and degree parameters were approximated by the covariance values calculated 
on the simulated data (see above). 
  We ran this procedure, as well as the Fisher method, for six representative tumor-
type cohorts (Breast-AdenoCa, CNS-GBM, ColoRect-AdenoCa, Lung-AdenoCa, Uterus-
AdenoCa, and meta-Carcinoma) and found that the Brown combined p-values generally 
followed the null distribution as expected (Extended Data Fig. 3b). The Fisher combined p-
values were significantly inflated (Extended Data Fig. 3b), confirming that dependencies 
existed between the results reported by the various driver detection algorithms. 
  We next explored whether it was possible to reduce the number of algorithm runs 
required to complete these calculations for all tumor-type cohorts by computing the 
covariance values on observed data instead of simulated data. In each of the six 
representative tumor-type cohorts, we calculated the empirical covariances on the observed 
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data only and then computed the integrated Brown p-values on the observed data using the 
observed covariances. Significant genes identified using only observed covariances 
remained mostly unchanged from the significant genes identified using the simulated 
covariances (Extended Data Fig. 3d), and examination of the differences in the covariance 
values between the simulated estimations and the observed estimations revealed only minor 
differences in values (Extended Data Fig. 3c). The significant drivers presented in this study 
were identified using this final approach – e.g., by computing integrated Brown p-values 
using estimations of covariance on observed data only. 
Integration of p-values from observed data was performed for 42 tumor-type cohorts 
and 13 target element types. Methods were selected for each given data set (see “Selecting 
methods to include in the integration of observed p-values”, below) and raw p-values smaller 
than 10-16 were trimmed to that value before proceeding with the integration. Methods with 
missing data for a given element (i.e., ones that failed to report a p-value for a given 
element) were excluded from the calculation for that element, and therefore in some cases 
the integrated Brown p-value was computed from p-values reported by only a subset of all 
the driver detection algorithms contributing results for that data set. 
 
Selecting methods to include in the integration of observed p-values 
In some cases, individual driver detection algorithms reported p-values for a given data set 
that deviated strongly from the expected uniform null distribution. These were methods for 
which the quantile-quantile (QQ) plots demonstrated considerable inflation. We removed 
results that reported an unusual number of significant hits by calculating, for each set of 
results, the number of significant elements found by each individual method using the 
Benjamini-Hochberg FDR with q<0.1 as the significance threshold. Any single method that 
reported four times the median number of significant elements identified by individual 
methods was discarded from the integration. In a separate analysis, we found that removing 
methods that yielded fewer hits than the median (i.e., methods with deflated QQ-plots) did 
not affect the number of significant genes identified through the integration of the reported p-
values (Extended Data Fig. 3d); hence we did not remove such methods. 
 
8. Post-filtering of candidates (Esther Rheinbay, Morten Muhlig Nielsen, Lars Feuerbach, 
Henrik Tobias Madsen) 
Post-filtering of significant hits was performed to remove those with accumulation of 
mutations caused by sequencing problems or mutational processes. In particular, we applied 
the following: (i) at least three mutations are present in the element, (ii) mutations are 
present in at least three patients of the tested cohort, (iii) less than 50% of mutations are 
located in palindromic DNA sequence22, (iv) more than 50% of mutations are located in 
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mappable genomic regions (CRG alignability, DAC blacklisted regions and DUKE 
uniqueness32; (v), less than 50% of mutations occur near indels, (vi) a site-specific noise 
filter (see below); and (vii) manual review of sequence evidence for novel drivers. For 
lymphomas, which contain regions of somatic hypermutation caused by AID enzyme activity, 
we (viii) further required less than 50% of mutations contributed by this process; and for 
Skin-melanoma, we (ix) excluded mutations occurring in the extended (CTTCCG) context 
that contributes to promoter hotspot mutations in this tumor type33,34,35. Even after this motif-
based filter, a large number of promoter and 5’UTR regions remained in the list of 
candidates. We, therefore, marked these as likely due to failed repair in TF occupied sites 
since it is unclear how many of them are true or false drivers. Additionally, elements that 
failed manual mutation review were filtered out at this stage.  
 
Site-specific noise filter 
Genomic positions of mutations in each significant hit were analyzed in all normal control 
samples to assess the position-specific noise-level. Therefore, for each of the three non-
reference nucleotides a and cohort c ϵ C the relative frequency of normal samples which had 
at least two reads supporting the alternative allele a were calculated as p(a,c) ϵ [0;100]. The 
noise score was then computed as !∈! 𝑙𝑜𝑔!"(𝑝(𝑎, 𝑐) + 1) . Mutations at positions with a 
score > 20 for at least one of the non-reference nucleotides were flagged. Elements for 
which the number of mutations at flagged positions exceeded 20% were removed. 
 
DNA palindromes 
We define a palindrome as a sequence of DNA followed by its complementary reverse with a 
sequence of variable length in between (Fig. 3d). It is hypothesized that these palindromes 
can temporarily form DNA hairpins36. While in the hairpin state the loop region is single-
stranded and open to attack by APOBEC enzymes. Based on observations in breast cancer 
whole genome sequences37, we decided to consider palindromes with a minimal repeat 
length of 6 bp and an intervening sequence (loop) length of 4-8 bp. We call these regions 
genome-wide using the algorithm described in Ye et al.38 however using our own 
implementation (https://github.com/TobiasMadsen/detectIR). In total, we find 7.3 M 
palindrome regions covering a total of 135.2 MB of which 33.6 MB are loop sequence. 
 
Computing the false discovery rate 
We controlled the false discovery rate (FDR) within each of the sets of tested genomic 
elements by concatenating all integrated Brown p-values from across all tumor-type cohorts 
and applying the Benjamini-Hochberg procedure17 to the integrated Brown p-values. A q-
value threshold of 0.1 was chosen to designate cohort-element combinations as significant 
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hits. In addition, we defined cohort-element combinations in the range 0.1≤ q<0.25 as “near 
significance”. We next applied several additional, mutation-based filtering criteria to each 
significant or near-significant candidate and assigned p-values of 1 to candidates that failed 
these filtering criteria. Final Benjamini-Hochberg FDR values were then re-calculated on the 
adjusted sets of integrated Brown p-values to arrive at a list of candidate driver cohort-
element combinations. 
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9. Sensitivity and precision analysis of driver predictions (Iñigo Martincorena) 
All methods employed in this study were shown to have a low rate of false positives when 
run on a series of neutral simulated datasets without driver mutations. To evaluate the 
sensitivity and precision of different methods and particularly of our approach for p-value 
integration, we compared their relative performance in detecting known cancer genes when 
applied to protein-coding genes. As a reference gold-standard set of known cancer genes 
we used a list of 603 genes from the manually-curated Cancer Gene Census v80 database. 
Results are shown in Extended Data Fig. 4. 
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10. Gene expression analyses (Samir B. Amin, Morten M. Nielsen, Andre Kahles, Nuno 
Fonseca, Lehmann Kjong, members of the PCAWG Transcriptome Working Group and 
Jakob Skou Pedersen) 
 
To extend the RNAseq-based expression profiling of GENCODE annotations provided by 
the PCAWG Transcriptome Working Group39, we profiled an extended set of gene 
annotations, including a comprehensive set of non-coding RNAs (described above and at 
Synapse:syn5325435).  
 
The profiling used the docker-based workflow described in 39 for 1,180 RNA-seq donor 
libraries, matched to WGS data across 27 different cancer types39. In brief, raw sequence 
reads from donor libraries were uniformly evaluated for QC using FastQC tool, and 
subsequent alignment was performed on QC-passed libraries using two methods: STAR 
(v2.4.0i)40 and TopHat2 (v2.0.12)41. Resulting QC-passed bam files were independently 
used to quantify extended RNA-seq annotations at the gene-level counts using htseq-count 
method with following parameters: -m intersection-nonempty --stranded=no --idattr gene_id. 
This step resulted in two sets of gene-level counts files per donor library which were 
independently normalized using FPKM normalization and upper quartile normalization 
(FPKM-UQ). The final expression values were provided as a gene-centric table (rows as 
genes, columns as samples) with each value representing an average of the TopHat2 and 
STAR-based alignments FPKM values. Gene-centric tables based on both, GENCODE and 
extended RNA-seq annotations are available at Synapse data portal: syn2364711. Docker-
based workflow for quantifying extended RNA-seq annotations is at 
https://github.com/dyndna/pcawg14_htseq  
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11. Normalization for copy number variation (Henrik Tobias Madsen, Morten Muhlig 
Nielsen, and Jakob Skou Pedersen) 
To account for the effects of somatic copy number alterations (SCNAs) on expression, we 
used two different approaches to create two additional versions of the expression profiles: 
First a conservative approach where we remove all samples not having the regular bi-allelic 
copy number for the gene in question. Second a less conservative approach where we build 
a regression model  of expression data based oncopy number (CN) data, and then tested for 
an effect of somatic mutations on the residual (i.e. the expression that is not explained by 
copy number). 
  
Generally the higher the copy number of a particular gene the higher expression. 
The relationship between copy number and gene expression is not strictly linear, as various 
feedback mechanisms in the cell try to compensate for the mostly deleterious effects of 
SCNAs. This is known as dosage compensation and has been studied extensively in the 
context of mammalian sex chromosomes, but also in evolution of yeast and in diseases 
caused by aneuploidy42–45. We therefore fit a linear regression model between the logarithm 
of expression and the logarithm of CN. This effectively amounts to a power-regression 
model. 
 
A number of factors makes it hard to learn the regression parameters for each gene and 
cancer type in isolation. (i) for some cancer types we have only a limited number of samples; 
(ii) for some genes there is not much variation in CN; and (iii) the variation in expression 
between samples is generally high. We overcome these problems by employing a mixed 
model strategy, that allows sharing of information between genes, effectively regularizing the 
parameter estimates for gene cancer-type combinations that carry little information on their 
own. 
 
Let  and  denote the expression and SCNA measurement respectively 
for gene, , in cancer-type, , and sample  respectively. We then define: 
 
, 
 
where  and  are fixed effects, whereas  and  are random effects, with 
 and . Finally the residual is . 
Using this model we infer a global SCNA to expression regression, , but allow some 
regularized gene-specific and gene/cancer type-specific variation:  and .  
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Thus we exploit the similarity across genes and similarity within genes across cancer types. 
 
Since the variance increases with the absolute value of the explanatory variable associated 
with a random slope, this kind of mixed model display heteroskedasticity. Furthermore the 
model is not invariant under scaling of the explanatory variable, in this case SCNA. We 
centralise  SCNA, such that normal diploid regions have the least variance. 
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12. Mutation to expression association (Morten Muhlig Nielsen, Henrik Tobias Madsen, 
and Jakob Skou Pedersen) 
 
Mutation to expression association was calculated using non-parametric rank sum based 
statistics on z-score normalized expression values. This equalizes expression mean and 
variance for each cancer type and is a way to allow for comparison across cancer types. For 
comparisons of expression in mutated vs non-mutated (wild-type) cases within the same 
cancer type, the test reduces to the Wilcoxon rank sum test. For comparisons involving 
samples in multiple cancer types, such as meta-cohorts and pan-cancer cohorts, the statistic 
and associated p-value is still the non-parametric Wilcoxon rank sum test, and thus no 
assumptions regarding distribution of z-score expressions are made. Tied expression values 
were broken by adding a small random rank robust value. Association estimates were 
performed based on original expression values as well as the two copy-number normalized 
expression sets mentioned above. Fold difference values were calculated per mutation as 
the log2 ratio of the expression of the mutated tumor to the median of all wild-type tumors of 
the same cancer type. Reported Fold Difference values for an element with multiple 
mutations represent the median fold difference of all mutations in that element. 
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13. Copy number analyses (Esther Rheinbay) 
We surveyed significant focal copy number alterations for candidate driver genes as 
orthogonal evidence for their “driverness”. Significant copy number alterations were obtained 
from the TCGA Copy Number Portal (http://portals.broadinstitute.org/tcga/home), analysis 
2015-06-01-stddata-2015_04_02 regular peel-off, a database of recurrent copy number 
alterations calculated by the GISTIC2 algorithm46 across >10,000 samples and 33 tumor 
types from TCGA. GISTIC2 results were included for candidate drivers if a gene was 
significant (residual q<0.1) and was located within a peak with ≤ 10 genes. Visualization was 
performed with the Integrative Genomics Viewer (IGV)47.  
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14. Power Calculations (Esther Rheinbay) 
Calculation of mutation detection sensitivity. Average detection sensitivity, the power to 
detect a true somatic variant, was calculated using a binomial model across all exon-like 
regions for different genomic element types as previously published27,48. Detection sensitivity 
was based on sequencing coverage and estimated clonal variant allele fraction from 60 
representative PCAWG alignments from the pilot cases (https://doi.org/10.1101/161562; 
Supplementary Table 7). Clonal allele fraction was estimated based on PCAWG consensus 
purity and ploidy estimates (doi: https://doi.org/10.1101/161562) as purity/(average ploidy)48. 
Element-wise averages were calculated as average across all exons for a given element.  
  
Estimation of total number of promoter hotspot mutations. Detection sensitivity for all 
patients was calculated for the two most recurrent TERT promoter hotspot sites 
(chr5:1295228, chr5:1295250; hg19) using total read depth at these positions, sample purity 
and average ploidy. For each cohort, the number and percentage of powered (≥90%) 
patients was obtained. The number of total expected mutations was then inferred as number 
of observed (called) mutations divided by the fraction of patients powered. The number of 
“missed” mutations is the difference between the total expected and observed mutations. 
Percentages of these numbers were calculated relative to the size of individual patient 
cohorts. Confidence intervals (95%) on the total percentage of patients with a TERT hotspot 
mutation were calculated using the beta distribution. Poisson confidence intervals were 
calculated for the number of missed mutations in the PCAWG cohort. Note that the inference 
of TERT mutations assumes exactly one mutation per patient. Estimates for the FOXA1 
promoter hotspot mutation (chr14:38064406; hg19) were conducted using the same 
procedure. 
 
Calculation of the minimum powered mutation frequency in a population. Power to 
discover driver elements mutated at a certain frequency in the population were conducted as 
described before21,49, but solving for the lowest frequency for a driver element in the patient 
population that is powered (≥90%) for discovery. The calculation of this lowest frequency 
takes into account the average background mutation frequencies for each cohort/element 
combination, the median length and average detection sensitivity for each element type, 
patient cohort size, and a global desired false positive rate of 10%.  
  
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
59 
15. Associations between mutation and signatures of selection: loss of 
heterozygosity and cancer allelic fractions (Federico Abascal, Iñigo Martincorena) 
For protein-coding sequences mutation recurrence can be analysed in the context of the 
functional impact of mutations (e.g. missense, truncating) to better distinguish the signal of 
selection. In contrast, estimating the functional impact of mutations in non-coding elements 
of the genome is a difficult, yet unsolved problem. To overcome this limitation and be able to 
compare selection signatures for both coding and non-coding elements under a similar 
framework, we developed two measures of selection which are agnostic to the functional 
impact of mutations. 
 
Association between mutation and loss of heterozygosity 
When a tumour carries a driver mutation in one allele of a given gene, it may be the case 
that a second hit on the other allele confers a growth advantage and is positively selected. 
When one of the events involves the loss of one of the alleles the process is referred to as 
loss of heterozygosity (LOH). This kind of biallelic losses are typical of, but not exclusive to, 
tumour suppressor genes (TSGs).  
 
For each gene, we build a 2x2 contingency table indicating the number of cases in which the 
gene was mutated or not and the number of cases in which the gene was subject to LOH or 
not. We applied a Fisher’s exact test of proportions to identify which genes showed an 
excess of LOH associated to mutation. P-values were corrected with the FDR method to 
account for multiple hypotheses testing. This analysis was applied to each tumour type and 
cohort separately and proved very successful in identifying TSG as well as some oncogenes 
(OGs) as well. 
 
Association between mutation and cancer allelic fractions 
Driver mutations that provide an advantage for tumour cells are expected to show higher 
allelic fractions based on different interacting processes, including: early selection; 
amplification of the locus carrying the driver mutation; loss of the non-mutated locus (LOH). 
Comparing cancer allelic fractions (CAF) can be informative to detect signatures of selection, 
both for TSGs and OGs. 
 
CAFs are defined here as the proportion of reads coming from the tumour and carrying the 
mutation. To transform observed fractions (VAFs) into CAFs, tumour purity and local ploidy 
needs to be taken into account according to the following formula: 
 
CAF = VAF * (Lp * Pt + 2 * (1 - Pt)) / (Lp * Pt)  
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Where Lp corresponds to the local ploidy for the mutated locus, and Pt denotes the tumour 
purity. Ploidy and tumour purity predictions were obtained from Dentro et al (in preparation). 
 
To determine whether CAFs for a given gene or element were higher than expected we 
compared them to the CAFs observed in flanking regions. To define flanking regions we took 
2 kb at each side of the gene/element, excluding any eventually overlapping coding exon, 
and also included introns (if present). The two sets of CAFs associated to each 
gene/element, i.e. those CAFs lying within the gene and those flanking it, were compared 
with a t-test to detect significant deviations. P-values were corrected with the FDR method. 
This approach was able to identify most known TSGs and OGs. 
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16. Signals of selection in aggregates of non-coding regions of known cancer genes  
(Federico Abascal, Iñigo Martincorena) 
We conducted a series of analyses on regions combined across genes to determine whether 
the paucity of driver mutations found in non-coding regions was related to lack of statistical 
power in single-gene analyses. This analysis also aimed to estimate how many driver 
mutations present in cancer genes were missed in this study. For protein-coding sequences, 
the number of driver mutations was estimated using dN/dS ratios as described in (50). For 
non-coding, regulatory regions of protein-coding genes (Promoter and UTRs), we relied on a 
modified version of the NBR negative binomial regression model described above (Section 
5) to quantify the overall excess of driver mutations. We applied a second approach to 
determine whether there was an enrichment of LOH associated to mutations in the different 
types of non-coding regions associated to protein-coding genes. 
 
Observed vs. expected numbers of mutations based on the NBR mutation model 
NBR was used to estimate the background mutation rate expected across cancer genes, 
using a conservative list of 19,082 putative passenger genes as background. The resulting 
model is used to predict the numbers of expected SNVs and indels per element type per 
gene, and aggregate sums across genes. For this analysis we selected a reduced but 
diverse set of 142 cancer genes, encompassing 27 focally amplified and 22 deleted genes 
found by TCGA and present in the Cancer Gene Census51, and 112 genes with a significant 
signal of selection in this study (q<0.1) and present in the Cancer Gene Census. The list of 
142 genes can be found in Supplementary. Table 7. To be as accurate as possible, we 
used a diverse set of covariates in the NBR model, including: local mutation rate (estimated 
on neutral regions +/- 100 kb around each gene), detection sensitivity (defined as the 
element-average proportion of callable samples per site according to MuTect), gene 
expression covariates (first 8 principal components of the matrix of average gene expression 
values in each tumour type, as well as two binary variables marking the 500 genes with 
highest expression values in any tumour and 1,229 genes with a maximum FPKM lower than 
0.1 across tumour types), and averaged copy-number calls for each gene across all samples 
(see Supplementary Note for more details). For each element type, the sum of observed 
mutations across the 142 cancer genes were compared to the sum of the expected rates to 
estimate the excess of mutations in regulatory and coding regions of cancer genes. An 
excess of observed mutations provides an estimate of the number of driver events18. 
Confidence intervals were calculated using the equation for the ratio of two Poisson 
observations, which are the number of mutations in the list of known cancer genes and in the 
list of passenger genes. It is important to know that these confidence intervals do not capture 
uncertainty in the background model and should be interpreted with caution. For this reason, 
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we systematically evaluated the impact of a diverse array of covariates on our estimates 
(see Supplementary Note). We also note that this test can underestimate the number of 
non-coding drivers since some driver mutations can be present in the list of putative 
passenger genes, although this effect is expected to be quantitatively small if the density of 
driver mutations in regulatory regions of known cancer genes is higher than in those of 
putative passenger genes. 
 
Mutation-LOH association for aggregates of genes 
For this analysis we combined data across known cancer genes, including 603 genes in the 
Cancer Gene Census v80 and 154 additional significantly mutated genes found by exome 
studies18,21. To estimate whether there was an excess of LOH associated to mutation in 
regulatory and coding regions of cancer genes, we calculated the fold change in LOH for the 
aggregate of cancer genes and normalized it dividing by the fold change observed in 
passenger genes. Confidence intervals were estimated using parametric bootstrapping 
(100,000 pseudoreplicates) for both cancer and passenger genes. 
 
 
 
  
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/237313doi: bioRxiv preprint first posted online Dec. 23, 2017; 
63 
17. Mutational process and indel enrichment (Federico Abascal, Iñigo Martincorena) 
After noticing the skewed distribution of indel lengths in genes like ALB, SFTBP, NEAT1 and 
MALAT1, we carried a search for other genes showing the same pattern, which may be 
subject to the same mutational process. For every gene we record the proportion of indels of 
length 2-5 bp out of the total number of indels and compared this proportion with the 
background proportion using a binomial test. The background proportion was calculated 
using all protein-coding and lncRNAs genes. For every gene we also calculated the indel 
rate and compared it to the background indel rate using a binomial test. Both sets of p-
values were independently corrected with the FDR method. The analysis was done for each 
tumour type separately. Genes with a q-value < 0.1 both for enrichment in 2-5 bp indels and 
for higher indel rates were further analyzed as candidates to be under the process of 
localized indel hypermutation described in this study. The levels of expression of these 
genes were analysed across all tumour types. 
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18. Mutations association to splicing (Andre Kahles) 
For the assessment of the relationship between mutations in the U2 locus upstream of 
WDR74 and local changes in alternative splicing, we analysed changes in the percent-
spliced-in (PSI) value52 of alternative splicing events located in WDR74 relative to the given 
genotype. The analysis was based on four different alternative splicing event types extracted 
and quantified by the PCAWG Transcriptome Working Group (exon skip, intron retention, 
alternative 3’ splice site, alternative 5’ splice site)39. In total we analysed 116, 103, 27 and 98 
events, respectively, for the above event types. We then filtered the events for a minimum of 
expression evidence (non-NaN PSI) in at least 10 samples, presence of the alternate allele 
together with expression evidence in at least 5 samples, and a minimum absolute distance 
of mean PSI values of alternate and reference group of 0.05. Based on the selected events, 
we retained 3, 3, 1 and 0 events for analysis. Using an ordinary least squares model with the 
genotypes as factors and the the PSI values as responses, we computed p-values and the 
variance explained by presence of mutations. Multiple testing correction followed the 
Bonferroni method. 
 
To assess the relationship between mutations in the U2 locus upstream of WDR74 and 
global changes in splicing, we used two global splicing statistics. We measured the amount 
of splicing as the number of edges in the splicing graph of a gene in a given samples. All 
splicing graphs were taken from the analyses of the PCAWG Transcriptome Working 
Group39. For each sample, we computed the mean number of splicing edges over all genes, 
resulting in the extent of splicing per sample. We measured the extent of splicing as how far 
each event is outlying from the mean over all event in the same cancer type (encoded by 
project code x histotype). The splicing outlier values per sample and gene were taken from 
the PCAWG Transcriptome Working Group analyses39. The mean over all genes of a 
sample was taken as a statistic for the extent of splicing. 
 
For both statistics, we again used an ordinary least squares model as described above to 
model the relationship between genotype and splicing. As splicing is highly tissue 
dependent, we included the project codes as additional factors, accounting for both tissue 
specificity as well as possible underlying batch effects. To extract the amount of additional 
variance explained through the presence of mutations, we computed one model on project 
codes and presence of mutations and one model on project codes alone. For the model, we 
only included samples of project codes, where we had at least one sample with a mutation 
present, resulting in a total of 618 samples over 14 project codes. 
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19. Structural variation analysis (Morten Muhlig Nielsen, Lars Feuerbach) 
Structural variant data was provided by the PCAWG Structural Variation Working Group. 
The data provide p-values for the observed breakpoint counts in 50kb bins along the 
genome. Candidate elements were overlapped with the bins, and fisher’s method was used 
to calculate a single p-value for each element. The set of element p-values were corrected 
with the FDR method. 
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20. RNA structural analysis (Radhakrishnan Sabarinathan, Ciyue Shen, Chris Sander, 
Jakob Skou Pedersen) 
In order to test if the observed mutations (SNVs) in the RMRP gene are biased towards high 
RNA secondary structure impact, we performed a permutation test by following the steps 
used in oncodriveFML24 together with the predicted structural impact scores from RNAsnp53. 
At first, the RNAsnp was run with the options -m 1 -w 300 and other default parameters to 
obtain the minimum correlation coefficient (r_min) score for each possible mutations in the 
RMRP gene. The r_min scores were then transformed, 1-((r_min+1)/2), to range between 0 
and 1, where 1 indicates high structural impact score.  Further, we followed the steps of 
oncodriveFML (see section ‘oncodriveFML’ for more details) with 1,000,000 randomizations 
and by using per sample mutational signatures (i.e., the probability of observing a mutation 
in a particular tri-nucleotide context in a given sample) to compute the p-value at the cohort 
and sample level. 
 
Furthermore, the RNA secondary structure impact scores (r_min) of indels 
(insertions/deletion) were computed by using a modified version of RNAsnp (since the 
current version of RNAsnp is limited to substitutions only). Briefly, we first computed the 
base pair probability matrices of wild-type and mutant sequences (by taking into account the 
insertion or deletion) and then adjusted the size of matrices to be equal (by introducing 
additional rows and columns with zeros in one of the matrices with respect to insertion or 
deletion). Further, by following the steps of RNAsnp, we computed the r_min score. The 
structure shown in Fig. 6d is based on the conserved secondary structure annotation 
obtained from Rfam (RF00030)54. 
 
Tertiary structure contacts in RMRP were predicted using evolutionary couplings co-variation 
analysis (EC analysis 55) of the multiple sequence alignment of 933 eukaryotic RMRP 
sequences from Rfam (RF00030). The EC analysis (software available at 
https://github.com/debbiemarkslab/plmc) was run with the options -le 20.0, -lh 0.01, -t 0.2, -m 
100 and the top 100 interactions were chosen as predicted contacts, either in secondary or 
tertiary structure, depending on local context. As no experimental 3D structure or cross-
linking experiments of the mammalian RMRP are available, interaction sites were inferred by 
homology to the partially known yeast RMRP crystal structure. We (1) aligned the human 
RMRP sequence with the Saccharomyces cerevisiae RMRP sequence using the sequence 
family covariance model from Rfam and (2) mapped the locations of RNA-protein 
interactions within 4Å56 from the crystal structure and the experimentally determined RNA-
protein crosslinking sites57, and RNA substrate crosslinking sites58 from the yeast sequence 
to the human RMRP sequence. For the crosslinking sites, a ±3 nucleotide window is 
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reported as the interaction site. In order to test if the locations of the observed indels are 
biased towards tertiary structure, protein- or substrate-interaction sites, 1,000,000 
randomizations of five indels were performed assuming uniform distribution of indels across 
the RMRP gene body, and an empirical p-value was calculated (P = .08), showing a 
potential for functional impact. 
 
Two different overlapping deletion calls in the RMRP gene body were observed in the same 
thyroid cancer patient. After manual inspection of the tumor and normal bam files, it was 
found that these calls were based on the same mutational event.  
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21. Cancer associated germline variant distance to non-coding driver candidates. 
(Morten Muhlig Nielsen) 
We used a set of genome-wide significant cancer associated germline SNPs (n=650) from 
the NHGRI-EBI GWAS catalog59 as collected by Sud et al60. We evaluated the genomic 
distance from candidate non-coding drivers to the closest germline variant. All distances 
were above 50 kb with the exception of the TERT promoter which was 1 kb away from a 
coding variant (rs2736098) in the TERT gene.  
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1. Overview of non-coding hotspots in top 50 not categorized in main text 
Six of the 35 non-coding hotspots in top 50 are not assigned to the mutational processes 
described in the main text and highlighted in Fig. 1b. Below we describe these in detail. 
 
Four of the six remaining non-coding hotspots were found on the X chromosome 
(X:116579329, X:7791111, X:83966025, and X:83967552). The mutations in these hotspots 
were mainly contributed by males (61-94% of mutations per hotspot), suggesting the 
possibility of uncaught noise. One of these hotspots is located in palindromic DNA 
(X:7791111). The DNA sequence around this position is composed of two mononucleotide 
repeats of pairing bases (ATTTTTAAAAAAAAAT), which fits our definition of palindromic 
structures (Methods). The sequence context around this hotspot do not match the sequence 
recognized by APOBEC enzymes1 and the hotspot had a low APOBEC signature probability 
(Fig. 1b). It is therefore unlikely to be caused by the same mutational processes as the other 
palindromic hotspots in the top 50 hotspots, but rather likely represents noise associated 
with homopolymer runs (PCAWG variants paper).  
 
A hotspot (3:164903710) contained mutations in multiple cancer types with most mutations 
contributed by Liver-HCC (6/17). It is located about 1 kb downstream of SLITRK3, two base 
pairs from an annotated CTCF transcription factor binding site. CTCF sites and the base 
pairs immediately downstream are known to be highly mutated in several cancer types 
including Liver-HCC. This position is lowly conserved, suggesting that it would not have a 
functional impact2. 
 
The last non-coding hotspot (1:103599442) had a high proportion of mutations attributed to 
the COSMIC5 signature. It overlaps a repetitive LINE region, suggesting potential mapping 
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issues. Moreover, the position is flanked by two other positions, two base pairs away in both 
directions, which also have mutations in the same samples and reads, however these 
positions were called problematic in the Panel-of-Normals (PoN) filter, further suggesting 
mapping issues. 
 
 
2. Discussion of additional significant non-coding elements 
WDR74 promoter 
The WDR74 promoter has already been suggested as a potential driver in several studies3–6. 
However, we found that mutations are concentrated inside a U2 RNA where the density of 
putative polymorphisms is abnormally high. This outstanding level of diversity could in 
principle be due to higher mutability in the germline. However, given the repetitive nature of 
the U2 element (there are hundreds of copies in the genome) and the extreme levels of 
putative diversity, it is more likely that this region is a source of mapping artefacts. This 
observation raise concerns about the validity of WDR74 promoter and, hence, on its 
potential as a cancer driver (Extended Data Fig. 10). 
 
TMEM107 3’UTR 
The case of the TMEM107 3’UTR is very similar to that of the WDR74 promoter. There is a 
small RNA (SNORD118) embedded in the 3’UTR, and is there where most mutations 
concentrate. In PCAWG normals data there is a remarkable excess of putative SNP diversity 
in this element. (Extended Data Fig. 10). 
 
Additional non-coding RNAs hits  
Eleven additional ncRNAs or ncRNA promoter hits, not described in detail in the main text, 
passed the flagging of potential false positive hits (RNU6-573P, RPPH1, RNU12, TRAM2-
AS1, G025135, G029190,RP11-92C4.6 and promoters of RNU12, MIR663A, RP11-
440L14.1, and LINC00963). The driver role of these were generally not supported by 
additional lines of evidence and lacked functional evidence or appeared to be affected by 
technical artefacts. They are described individually below. 
 
RNU6-573P 
The small RNA RNU6-573P is detected in Endocrine pancreas (q = 7.3x10-4) with three 
mutations. However, it appears to be a nonfunctional pseudogene recently inserted in the 
human lineage. Not only the locus, but the wider region is subject to increased mutational 
burden, further supporting that mutational mechanisms or technical issues rather than 
selection underlies the mutational recurrence. 
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RNU12 
RNU12 is a spliceosomal RNA, which was found significant in Lymph-BNHL (q = 5.0x10-2) 
and in the  Hematopoietic system meta cohort (q = 7.0x10-2). The mutation rate is 1.6 times 
higher inside the gene in pan-cancer compared to the flanking regions. However, the 
mutation rate is 4 times higher in gnomAD, which renders it as a likely problematic region. 
Significance in the promoter of RNU12 was also identified in Lymphomas (q = 3.5x10-2) and 
the Hematopoietic system meta cohort (q = 1.8x10-6). But this region is overlapping the 
promoter of POLDIP3 (Polymerase delta-interacting protein 3), which makes interpretation 
difficult. 
 
MIR663A 
The promoter of MIR663A was recurrently mutated in the carcinoma meta cohort (q = 
7.2x10-4). It is the primary transcript of MiR-663, which has tumorigenic functions in gastric 
cancer and nasopharyngeal carcinoma7. The mutation rate is 1.2 times higher inside the 
element compared to the flanking regions, but the mutation rate is 2.4 times higher in 
gnomAD. The mutations were also not correlated with expression. 
 
RPPH1 
RPPH1 forms the RNA component of the RNase P ribonucleoprotein, which matures 
precursor-tRNAs by cleaving their 5’ end8. It is transcribed from a divergent promoter 
together with the protein-coding gene PARP2, however, no association with expression was 
observed for either gene. The region has a high level of germline polymorphisms in normal 
samples indicative of a problematic region to map. 
 
TRAM2-AS1 
The promoter element of the antisense non-coding RNA TRAM2-AS1 is recurrently mutated 
in the Female reproductive system meta cohort (q = 0.10). The promoter is shared with the 
divergently transcribed protein-coding gene TRAM2. Interestingly, the promoter has 8 
mutations in other cohorts, which collectively associate with the expression of TRAM2 (P = 
0.03; carcinoma) but not TRAM2-AS1 (P = 0.9). It is uncertain which gene is controlled by 
this significant promoter element. 
 
G025135 
G025135 is a ncRNA element from MiTranscriptome9 identified here as a significant driver 
candidate in Lymph-CLL (q = 0.01). There are patients with many mutations, indicating that 
an unknown mutation process is at play leading to false driver prediction. 
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G029190 
The G029190 ncRNA is also from MiTranscriptome with significance in Kidney-RCC (q = 
0.04) and in the Kidney meta cohort (q = 0.05). It is located downstream of RAB11FIP3 and 
upstream of CAPN15. A possible function of this gene has not been established. 
 
LINC00963  
LINC00963 was found significant in the Kidney meta cohort (q = 0.04). It has many 
alternative transcripts with different TSSs and thus a large promoter. LINC00963 is known to 
be involved in the prostate cancer transition from androgen-dependent to androgen-
independent and metastasis via the EGFR signaling pathway10. The SNV mutation rate is 
generally high (0.05 mutations per position), although lower than the flanking regions (0.08).  
  
RP11-92C4.6 
RP11-92C4.6 is a predicted antisense ncRNA, which was identified as a significant driver 
candidate in the Breast meta cohort (q = 0.08). It is a short region with low conservation 
containing four SNVs. It is overlapping the COL15A1 protein-coding gene with the upstream 
promoter region. COL15A1 has previously been linked to ovarian cancer. It is unclear 
whether this ncRNA annotation is valid and whether these reflect true functional mutations. 
 
RP11-440L14.1 
The promoter of RP11-440L14.1 was identified as a candidate driver in the Carcinoma meta 
cohort with 14 mutations (q = 5.4x10-3). It has a hotspot position with four mutations 
overlapping two different deletions. The lncRNA is located between CPLX1 and PCGF3. The 
validity of the annotation and possible function for this lncRNA has not been established. 
 
 
3. Evaluation of splicing association of U2 mutations upstream of WDR74  
We hypothesized that the mutations observed in the evolutionarily conserved spliceosomal 
U2 RNA upstream of WDR74 may affect splicing. As prior sequencing evidence, 
summarised in the GENCODE version 19 gene annotations11, shows that the U2 is co-
transcribed as an alternative 5’ exon in some cases, it might play a role in splicing and 
regulation of the WDR74 transcript. We therefore both evaluated (A) whether the mutations 
associate with alternative splicing of the WDR74 gene; and (B) whether they associate with 
transcriptome-wide changes in splicing. 
 
A) We modelled the association of the the somatic mutations with the amount of alternative 
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splicing, as measured by percent-spliced-in values12, using ordinary least squares 
regression, which did not reveal any significant associations. For none of the seven tested 
alternative splicing events (three exon skips, three intron retentions, one alternative 3-prime 
splice site) the genotype was able to explain a substantial fraction of the observed variation. 
The largest R-squared value was 0.01 and no p-value reached nominal significance.  
 
B) A similar result was obtained for the relationship between the presence of U2 mutations 
and global changes in alternative splicing. Modeling the amount of alternative splicing on the 
ICGC project codes alone, which reflect cancer types and contributing institutions, we 
reached an R-squared value of 0.612, reflecting the strong relationship between splicing and 
tissue identity. Including the presence of somatic mutations in the model did not change this 
value. We obtained an analogous result for the extent of alternative splicing, reaching an R-
squared of 0.414 on the project codes alone and the same value when including the 
genotype into the model. 
 
In conclusion, we found no evidence for an association between mutations in the U2 
upstream of WDR74 and alternative splicing of WDR74 transcripts or global changes in 
splicing. 
 
 
4. Enrichment of protein-coding drivers 
Collectively, mutations occurring in the promoter region of the 757 cancer genes did not 
have a significantly different association with expression than synonymous mutations 
(Supplementary fig. 1a). Similarly, promoter and UTR mutations in cancer genes are not 
significantly enriched in LOH with respect to mutations in putative passenger genes 
(Supplementary fig. 1b). This is consistent with the prediction above that only a very small 
fraction of the mutations observed in the promoters and UTRs of known cancer genes are 
genuine driver events. 
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Supplementary figure 1:  a, Expression associated with mutations in coding and promoter 
regions of cancer genes. Z-score expressions associated with non-sense mutations deviate 
significantly from silent mutations, likely through nonsense mediated decay, whereas 
expressions associated with promoter mutations do not differ from that of silent mutations. 
Only mutations in diploid positions were used. b, Excess of LOH associated to mutation in 
regulatory and coding regions of cancer genes. The y-axes shows the ratio of fold changes 
in cancer vs. passenger genes, with fold changes representing the excess or depletion of 
LOH associated with mutation. 
 
 
5. Impact of covariates on the estimation of driver mutations in functional regions of 
cancer genes 
As described in Methods, we estimated the abundance of driver mutations in coding and 
regulatory regions (promoter and UTRs) of 142 known cancer genes using the NBR 
background model fitted on putative passenger genes. 
 
Different covariates were included to improve the fit of the model. The local mutation rate, 
calculated on neutral regions within +/-100 kb around each element, was included to account 
for regional variation of mutation rates. Detection sensitivity (d.s.) was averaged for each 
element using the MuTect estimates of callable sites from each sample. For genes in 
chromosomes X and Y, we did not have MuTect estimates and d.s. was imputed using a 
linear regression model of d.s. as a function of GC content. Detection sensitivity accounts for 
elements where the mutation rate is lower than expected just because of poor sequencing 
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coverage. A third type of covariate was included in the model to account for associations 
between gene expression levels and mutation rates. Starting with a matrix of mean FPKM 
expression values for each gene and tumour type, we log-transformed and scaled the 
expression matrix using pseudocounts and applied Principal Component Analysis to reduce 
the dimensionality. We selected the first 8 components as covariates, which together 
explained 95.5% of the variance. In addition, we added two additional covariates to account 
for non-linearity between expression and mutation rate in the tails of the expression 
spectrum. To accomplish this, we created two binary variables, one marking the 500 genes 
with highest maximum expression values across tumour types, the other marking 1,229 
genes whose expression did not exceed FPKM values of 0.1 in any tumour type. Finally, 
since tumours are rich in amplifications and deletions and these events may result in 
seemingly increased or decreased mutation rates, we included a copy-number covariate, 
calculated as the average copy number of each gene across all PCAWG samples. 
 
We intentionally selected a small set of cancer genes to estimate the abundance of driver 
mutations because with larger numbers of genes the signal of selection becomes weaker 
while any systematic bias may become more prominent. We noticed these biases becoming 
increasingly apparent when analyzing larger sets of genes. In an attempt to capture a 
diverse but relatively small group of cancer genes, we included Cancer Gene Census genes 
recurrently mutated by coding mutations in PCAWG and genes frequently altered by copy 
number gains or losses, as described in Methods. 
 
Supplementary Table 9 shows the impact of using different covariates on the 142 genes 
selected for this analysis. Reassuringly, this shows that the estimates are broadly consistent 
across models with different covariates, with variations typically within the confidence 
intervals of alternative models. This confirms that the overall conclusions are largely 
unaffected by the use of different models. Supplementary Figure 2 shows the results for 
the 142 genes and for a larger set of 603 genes from the Cancer Gene Census.  
 
To evaluate the performance of the NBR model, we compared the number of driver 
substitutions predicted by NBR in the CDS regions of the 142 cancer genes to the number 
predicted by dN/dS (calculated by dNdScv). dN/dS offers an independent estimate of the 
number of driver substitutions in a group of genes using the local density of synonymous 
mutations to estimate the neutral expectation13, instead of predicting the background 
mutation rate by extrapolation from putative passenger genes using a regression model. 
Reassuringly, in these 142 genes, NBR predicts 2,258 (CI95%: 2,127-2,382) driver 
substitutions and dN/dS predicts 2,384 (CI95%: 2,043-2,759). 
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Supplementary figure 2:  Estimation of the excess substitutions (left) and indels (right) in 
regulatory and protein-coding regions of cancer genes and for the 142 (left) genes and a 
larger set of genes from the Cancer Gene Census (right). Ratios of observed vs. expected 
number of mutations (top), the percentage of mutations predicted to be drivers (middle), and 
the total number of predicted drivers in all cancers and in each patient (bottom) are shown. 
 
 
6. Author contributions by category 
 
Driver discovery 
A.L., C.H., C.W., D.A.W., E.K., E.M.L., E.R., G.G., G.T., H.M.U., I.M., J.K., J.R., J.S.P., 
K.A.B., K.D., K.I., L.M., L.U.-R., M.M.N., M.P.H., N.A.S., P.D., P.J.C., R.J., S.B.A., T.A.J., 
T.T. and , Y.F. contributed and curated genomic annotations. C.H., C.W.Y.C., I.M., S.B.A. 
and Y.E.M. contributed randomized mutational data sets for driver discovery. A.L., A.G.-P., 
A.H., D.L., D.T., E.K., E.M.L., E.R., H.H., H.M., I.M., I.R., J.B., J.C.-F., J.D., J.F., J.M.H., 
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J.R., J.Z., K.C., K.D., K.I., L.L., L.M., L.S., L.U.-R., L.W., M.B.G., M.J., N.L.-B., O.P., P.D., 
Q.G., R.S., S.K. and S.S. contributed driver methods and results. E.R., G.G. and G.T. 
implemented results integration. A.K., C.v.M., C.V., G.T., H.H., I.M., J.R., L.F. and M.M.N. 
contributed driver results integration. C.H., C.W.Y.C., E.K., E.R., G.G., J.K., J.M.H., J.S.P., 
M.M.N. and R.I.P. contributed single site recurrence analysis. 
 
Candidate vetting and filtering 
E.R., F.A., H.H., H.T.M., J.K., L.F. and M.M.N. contributed individual candidate filters. A.L., 
C.H., C.W., E.K., E.M.L., E.R., F.A., G.G., G.T., H.H., H.M., H.M.U., J.K., J.M.H., J.S.P., 
K.D., L.F., L.S., M.M.N., M.S.L., N.A.S. and R.J. performed candidate vetting. 
 
Case-based analysis 
E.R., F.A., G.G., H.H., I.M., J.M.H., J.R., J.S.P., K.P., M.M.N. and M.P.H. contributed case-
based analysis. A.G.-P., A.H., A.L., C.H., D.C., D.T., E.K., E.R., F.A., G.G., G.T., H.H., H.K., 
I.M., J.C.-F, J.R., J.S.P., K.I., K.P., L.M., L.S., L.U.-R., L.W., M.A.R., M.B.G., M.M.N., M.S.L., 
N.A.S., N.L.-B., O.P., R.I.P., R.S., S.K. and Y.K. contributed results interpretation. A.K., 
J.S.P., K.A.B., K.-V.L., M.M.N., N.A.F., S.B.A., T.A.J. and T.T. contributed expression 
profiling (extended GENCODE set). A.K., C.V., D.C., H.M., H.T.M., J.R., J.S.P., K.I., L.W., 
M.A.R., M.M.N., M.S.L. and S.B.A. contributed mutation-to-expression correlation analysis. 
A.K., C.V., D.C., J.R., L.W., M.A.R., N.A.S. and Z.Z. contributed network or pathway 
analysis. R.S, Ciyue S., Chris S., and J.S.P. contributed structural RNA analysis. 
 
Power analysis and driver mutations at known cancer genes 
E.R. analysed SNV detection and driver discovery power. I.M. evaluated excess number of 
mutations at known drivers. F.A. and M.M.N. integrated additional evidence. 
 
Leadership and organizational work 
E.R., G.G. and J.S.P. contributed working group leadership. A.G.-P., D.A.W., E.K., E.R., 
G.G., G.T., I.M., J.R., J.S.P., L.F., L.M., M.B.G., N.L.-B., O.P., P.J.C., R.S. and S.K. 
contributed organization.  
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